From HandWiki
Short description: Central nervous system stimulant
2D structure of caffeine
3D structure of caffeine
Clinical data
Pronunciation/kæˈfn, ˈkæfn/
Other namesGuaranine
7-methyltheophylline[1] Theine
  • AU: A
Routes of
By mouth, insufflation, enema, rectal, intravenous
Drug classStimulant
ATC code
Legal status
Legal status
  • AU: Unscheduled
  • CA: Unscheduled
  • DE: Unscheduled
  • NZ: Unscheduled
  • UK: General sales list (GSL, OTC)
  • US: Unscheduled
  • In general: Legal for recreational use in most countries
Psychological: low[6]
Pharmacokinetic data
Protein binding25–36%[8]
MetabolismPrimary: CYP1A2[8]
Minor: CYP2E1,[8] CYP3A4,[8]
CYP2C8,[8] CYP2C9[8]
MetabolitesParaxanthine (84%)
Theobromine (12%)
Theophylline (4%)
Onset of action45 minutes–1 hour[7][9]
Elimination half-lifeAdults: 3–7 hours[8]
Infants (full term): 8 hours[8]
Infants (premature): 100 hours[8]
Duration of action3–4 hours[7]
ExcretionUrine (100%)
CAS Number
PubChem CID
PDB ligand
Chemical and physical data
Molar mass194.194 g·mol−1
3D model (JSmol)
Density1.23 g/cm3
Melting point235 to 238 °C (455 to 460 °F) (anhydrous)[10][11]

Caffeine is a central nervous system (CNS) stimulant of the methylxanthine class.[12] It is mainly used recreationally as a cognitive enhancer, increasing alertness and attentional performance.[13][14] Caffeine acts by blocking binding of adenosine to the adenosine A1 receptor, which enhances release of the neurotransmitter acetylcholine.[15] Caffeine has a three-dimensional structure similar to that of adenosine, which allows it to bind and block its receptors.[16] Caffeine also increases cyclic AMP levels through nonselective inhibition of phosphodiesterase.[17]

Caffeine is a bitter, white crystalline purine, a methylxanthine alkaloid, and is chemically related to the adenine and guanine bases of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). It is found in the seeds, fruits, nuts, or leaves of a number of plants native to Africa, East Asia and South America,[18] and helps to protect them against herbivores and from competition by preventing the germination of nearby seeds,[19] as well as encouraging consumption by select animals such as honey bees.[20] The best-known source of caffeine is the coffee bean, the seed of the Coffea plant. People may drink beverages containing caffeine to relieve or prevent drowsiness and to improve cognitive performance. To make these drinks, caffeine is extracted by steeping the plant product in water, a process called infusion. Caffeine-containing drinks, such as coffee, tea, and cola, are consumed globally in high volumes. In 2020, almost 10 million tonnes of coffee beans were consumed globally.[21] Caffeine is the world's most widely consumed psychoactive drug.[22][23] Unlike most other psychoactive substances, caffeine remains largely unregulated and legal in nearly all parts of the world. Caffeine is also an outlier as its use is seen as socially acceptable in most cultures and even encouraged in others.

Caffeine has both positive and negative health effects. It can treat and prevent the premature infant breathing disorders bronchopulmonary dysplasia of prematurity and apnea of prematurity. Caffeine citrate is on the WHO Model List of Essential Medicines.[24] It may confer a modest protective effect against some diseases,[25] including Parkinson's disease.[26] Some people experience sleep disruption or anxiety if they consume caffeine,[27] but others show little disturbance. Evidence of a risk during pregnancy is equivocal; some authorities recommend that pregnant women limit caffeine to the equivalent of two cups of coffee per day or less.[28][29] Caffeine can produce a mild form of drug dependence – associated with withdrawal symptoms such as sleepiness, headache, and irritability – when an individual stops using caffeine after repeated daily intake.[2][4][6] Tolerance to the autonomic effects of increased blood pressure and heart rate, and increased urine output, develops with chronic use (i.e., these symptoms become less pronounced or do not occur following consistent use).[30]

Caffeine is classified by the US Food and Drug Administration as generally recognized as safe. Toxic doses, over 10 grams per day for an adult, are much higher than the typical dose of under 500 milligrams per day.[31] The European Food Safety Authority reported that up to 400 mg of caffeine per day (around 5.7 mg/kg of body mass per day) does not raise safety concerns for non-pregnant adults, while intakes up to 200 mg per day for pregnant and lactating women do not raise safety concerns for the fetus or the breast-fed infants.[32] A cup of coffee contains 80–175 mg of caffeine, depending on what "bean" (seed) is used, how it is roasted (darker roasts have less caffeine), and how it is prepared (e.g., drip, percolation, or espresso).[33] Thus it requires roughly 50–100 ordinary cups of coffee to reach the toxic dose. However, pure powdered caffeine, which is available as a dietary supplement, can be lethal in tablespoon-sized amounts.



Main page: Chemistry:Caffeine citrate

Caffeine is used in:

  • Bronchopulmonary dysplasia in premature infants for both prevention[34] and treatment.[35] It may improve weight gain during therapy[36] and reduce the incidence of cerebral palsy as well as reduce language and cognitive delay.[37][38] On the other hand, subtle long-term side effects are possible.[39]
  • Apnea of prematurity as a primary treatment,[40] but not prevention.[41][42]
  • Orthostatic hypotension treatment.[43][42][44]
  • Some people use caffeine-containing beverages such as coffee or tea to try to treat their asthma.[45] Evidence to support this practice is poor.[45] It appears that caffeine in low doses improves airway function in people with asthma, increasing forced expiratory volume (FEV1) by 5% to 18%, with this effect lasting for up to four hours.[46]
  • The addition of caffeine (100–130 mg) to commonly prescribed pain relievers such as paracetamol or ibuprofen modestly improves the proportion of people who achieve pain relief.[47]
  • Consumption of caffeine after abdominal surgery shortens the time to recovery of normal bowel function and shortens length of hospital stay.[48]
  • Caffeine was formerly used as a second-line treatment for ADHD. It is considered less effective than methylphenidate or amphetamine but more so than placebo for children with ADHD.[49][50] Children, adolescents, and adults with ADHD are more likely to consume caffeine, perhaps as a form of self-medication.[50][51]

Enhancing performance

Cognitive performance

Caffeine is a central nervous system stimulant that may reduce fatigue and drowsiness.[12] At normal doses, caffeine has variable effects on learning and memory, but it generally improves reaction time, wakefulness, concentration, and motor coordination.[52][53] The amount of caffeine needed to produce these effects varies from person to person, depending on body size and degree of tolerance.[52] The desired effects arise approximately one hour after consumption, and the desired effects of a moderate dose usually subside after about three or four hours.[7]

Caffeine can delay or prevent sleep and improves task performance during sleep deprivation.[54] Shift workers who use caffeine make fewer mistakes that could result from drowsiness.[55]

Caffeine in a dose dependent manner increases alertness in both fatigued and normal individuals.[56]

A systematic review and meta-analysis from 2014 found that concurrent caffeine and L-theanine use has synergistic psychoactive effects that promote alertness, attention, and task switching;[57] these effects are most pronounced during the first hour post-dose.[57]

Physical performance

Caffeine is a proven ergogenic aid in humans.[58] Caffeine improves athletic performance in aerobic (especially endurance sports) and anaerobic conditions.[58] Moderate doses of caffeine (around 5 mg/kg[58]) can improve sprint performance,[59] cycling and running time trial performance,[58] endurance (i.e., it delays the onset of muscle fatigue and central fatigue),[58][60][61] and cycling power output.[58] Caffeine increases basal metabolic rate in adults.[62][63][64] Caffeine ingestion prior to aerobic exercise increases fat oxidation, particularly in persons with low physical fitness.[65]

Caffeine improves muscular strength and power,[66] and may enhance muscular endurance.[67] Caffeine also enhances performance on anaerobic tests.[68] Caffeine consumption before constant load exercise is associated with reduced perceived exertion. While this effect is not present during exercise-to-exhaustion exercise, performance is significantly enhanced. This is congruent with caffeine reducing perceived exertion, because exercise-to-exhaustion should end at the same point of fatigue.[69] Caffeine also improves power output and reduces time to completion in aerobic time trials,[70] an effect positively (but not exclusively) associated with longer duration exercise.[71]

Specific populations


For the general population of healthy adults, Health Canada advises a daily intake of no more than 400 mg.[72] This limit was found to be safe by a 2017 systematic review on caffeine toxicology.[73]


In healthy children, moderate caffeine intake under 400 mg produces effects that are "modest and typically innocuous".[74][75] As early as six months old, infants can metabolize caffeine at the same rate as that of adults.[76] Higher doses of caffeine (>400 mg) can cause physiological, psychological and behavioral harm, particularly for children with psychiatric or cardiac conditions.[74] There is no evidence that coffee stunts a child's growth.[77] The American Academy of Pediatrics recommends that caffeine consumption is not appropriate for children and adolescents and should be avoided.[78] This recommendation is based on a clinical report released by American Academy of Pediatrics in 2011 with a review of 45 publications from 1994 to 2011 and includes inputs from various stakeholders (Pediatricians, Committee on nutrition, Canadian Pediatric Society, Centers for Disease Control & Prevention, Food and Drug Administration, Sports Medicine & Fitness committee, National Federations of High School Associations).[78] For children age 12 and under, Health Canada recommends a maximum daily caffeine intake of no more than 2.5 milligrams per kilogram of body weight. Based on average body weights of children, this translates to the following age-based intake limits:[72]

Age range Maximum recommended daily caffeine intake
4–6 45 mg (slightly more than in 355 ml (12 fl. oz) of a typical caffeinated soft drink)
7–9 62.5 mg
10–12 85 mg (about ​12 cup of coffee)


Health Canada has not developed advice for adolescents because of insufficient data. However, they suggest that daily caffeine intake for this age group be no more than 2.5 mg/kg body weight. This is because the maximum adult caffeine dose may not be appropriate for light-weight adolescents or for younger adolescents who are still growing. The daily dose of 2.5 mg/kg body weight would not cause adverse health effects in the majority of adolescent caffeine consumers. This is a conservative suggestion since older and heavier-weight adolescents may be able to consume adult doses of caffeine without experiencing adverse effects.[72]

Pregnancy and breastfeeding

The metabolism of caffeine is reduced in pregnancy, especially in the third trimester, and the half-life of caffeine during pregnancy can be increased up to 15 hours (as compared to 2.5 to 4.5 hours in non-pregnant adults).[79] Current evidence regarding the effects of caffeine on pregnancy and for breastfeeding are inconclusive.[28] There is limited primary and secondary advice for, or against, caffeine use during pregnancy and its effects on the fetus or newborn.[28]

The UK Food Standards Agency has recommended that pregnant women should limit their caffeine intake, out of prudence, to less than 200 mg of caffeine a day – the equivalent of two cups of instant coffee, or one and a half to two cups of fresh coffee.[80] The American Congress of Obstetricians and Gynecologists (ACOG) concluded in 2010 that caffeine consumption is safe up to 200 mg per day in pregnant women.[29] For women who breastfeed, are pregnant, or may become pregnant, Health Canada recommends a maximum daily caffeine intake of no more than 300 mg, or a little over two 8 oz (237 mL) cups of coffee.[72] A 2017 systematic review on caffeine toxicology found evidence supporting that caffeine consumption up to 300 mg/day for pregnant women is generally not associated with adverse reproductive or developmental effect.[73]

There are conflicting reports in the scientific literature about caffeine use during pregnancy.[81] A 2011 review found that caffeine during pregnancy does not appear to increase the risk of congenital malformations, miscarriage or growth retardation even when consumed in moderate to high amounts.[82] Other reviews, however, concluded that there is some evidence that higher caffeine intake by pregnant women may be associated with a higher risk of giving birth to a low birth weight baby,[83] and may be associated with a higher risk of pregnancy loss.[84] A systematic review, analyzing the results of observational studies, suggests that women who consume large amounts of caffeine (greater than 300 mg/day) prior to becoming pregnant may have a higher risk of experiencing pregnancy loss.[85]

Adverse effects


Caffeine in coffee and other caffeinated drinks can affect gastrointestinal motility and gastric acid secretion.[86][87][88] In postmenopausal women, high caffeine consumption can accelerate bone loss.[89][90]

Acute ingestion of caffeine in large doses (at least 250–300 mg, equivalent to the amount found in 2–3 cups of coffee or 5–8 cups of tea) results in a short-term stimulation of urine output in individuals who have been deprived of caffeine for a period of days or weeks.[91] This increase is due to both a diuresis (increase in water excretion) and a natriuresis (increase in saline excretion); it is mediated via proximal tubular adenosine receptor blockade.[92] The acute increase in urinary output may increase the risk of dehydration. However, chronic users of caffeine develop a tolerance to this effect and experience no increase in urinary output.[93][94][95]


Minor undesired symptoms from caffeine ingestion not sufficiently severe to warrant a psychiatric diagnosis are common and include mild anxiety, jitteriness, insomnia, increased sleep latency, and reduced coordination.[52][96] Caffeine can have negative effects on anxiety disorders.[97] According to a 2011 literature review, caffeine use may induce anxiety and panic disorders in people with Parkinson's disease.[98] At high doses, typically greater than 300 mg, caffeine can both cause and worsen anxiety.[99] For some people, discontinuing caffeine use can significantly reduce anxiety.[100]

In moderate doses, caffeine has been associated with reduced symptoms of depression and lower suicide risk.[101] Two reviews indicate that increased consumption of coffee and caffeine may reduce the risk of depression.[102][103]

Some textbooks state that caffeine is a mild euphoriant,[104][105][106] while others state that it is not a euphoriant.[107][108]

Caffeine-induced anxiety disorder is a subclass of the DSM-5 diagnosis of substance/medication-induced anxiety disorder.[109]

Reinforcement disorders


Whether caffeine can result in an addictive disorder depends on how addiction is defined. Compulsive caffeine consumption under any circumstances has not been observed, and caffeine is therefore not generally considered addictive.[110] However, some diagnostic models, such as the ICDM-9 and ICD-10, include a classification of caffeine addiction under a broader diagnostic model.[111] Some state that certain users can become addicted and therefore unable to decrease use even though they know there are negative health effects.[112][113]

Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, with people preferring placebo over caffeine in a study on drug abuse liability published in an NIDA research monograph.[114] Some state that research does not provide support for an underlying biochemical mechanism for caffeine addiction.[2][115][116][117] Other research states it can affect the reward system.[118]

"Caffeine addiction" was added to the ICDM-9 and ICD-10. However, its addition was contested with claims that this diagnostic model of caffeine addiction is not supported by evidence.[2][3][119] The American Psychiatric Association's DSM-5 does not include the diagnosis of a caffeine addiction but proposes criteria for the disorder for more study.[109][120]

Dependence and withdrawal

Withdrawal can cause mild to clinically significant distress or impairment in daily functioning. The frequency at which this occurs is self-reported at 11%, but in lab tests only half of the people who report withdrawal actually experience it, casting doubt on many claims of dependence.[121] Mild physical dependence and withdrawal symptoms may occur upon abstinence, with greater than 100 mg caffeine per day, although these symptoms last no longer than a day.[2] Some symptoms associated with psychological dependence may also occur during withdrawal.[6] The diagnostic criteria for caffeine withdrawal require a previous prolonged daily use of caffeine.[122] Following 24 hours of a marked reduction in consumption, a minimum of 3 of these signs or symptoms is required to meet withdrawal criteria: difficulty concentrating, depressed mood/irritability, flu-like symptoms, headache, and fatigue.[122] Additionally, the signs and symptoms must disrupt important areas of functioning and are not associated with effects of another condition.[122]

The ICD-11 includes caffeine dependence as a distinct diagnostic category, which closely mirrors the DSM-5's proposed set of criteria for "caffeine-use disorder".[120][123]  Caffeine use disorder refers to dependence on caffeine characterized by failure to control caffeine consumption despite negative physiological consequences.[120][123] The APA, which published the DSM-5, acknowledged that there was sufficient evidence in order to create a diagnostic model of caffeine dependence for the DSM-5, but they noted that the clinical significance of the disorder is unclear.[124] Due to this inconclusive evidence on clinical significance, the DSM-5 classifies caffeine-use disorder as a "condition for further study".[120]

Tolerance to the effects of caffeine occurs for caffeine-induced elevations in blood pressure and the subjective feelings of nervousness. Sensitization, the process whereby effects become more prominent with use, occurs for positive effects such as feelings of alertness and wellbeing.[121] Tolerance varies for daily, regular caffeine users and high caffeine users. High doses of caffeine (750 to 1200 mg/day spread throughout the day) have been shown to produce complete tolerance to some, but not all of the effects of caffeine. Doses as low as 100 mg/day, such as a 6 oz (170 g) cup of coffee or two to three 12 oz (340 g) servings of caffeinated soft-drink, may continue to cause sleep disruption, among other intolerances. Non-regular caffeine users have the least caffeine tolerance for sleep disruption.[125] Some coffee drinkers develop tolerance to its undesired sleep-disrupting effects, but others apparently do not.[126]

Risk of other diseases

A protective effect of caffeine against Alzheimer's disease and dementia is possible but the evidence is inconclusive.[127][128] It may protect people from liver cirrhosis.[129] Caffeine may lessen the severity of acute mountain sickness if taken a few hours prior to attaining a high altitude.[130] One meta analysis has found that caffeine consumption is associated with a reduced risk of type 2 diabetes.[131] Regular caffeine consumption may reduce the risk of developing Parkinson's disease and may slow the progression of Parkinson's disease.[132][133][26]

Caffeine increases intraocular pressure in those with glaucoma but does not appear to affect normal individuals.[134]

The DSM-5 also includes other caffeine-induced disorders consisting of caffeine-induced anxiety disorder, caffeine-induced sleep disorder and unspecified caffeine-related disorders. The first two disorders are classified under "Anxiety Disorder" and "Sleep-Wake Disorder" because they share similar characteristics. Other disorders that present with significant distress and impairment of daily functioning that warrant clinical attention but do not meet the criteria to be diagnosed under any specific disorders are listed under "Unspecified Caffeine-Related Disorders".[135]


Torso of a young man with overlaid text of main side-effects of caffeine overdose.
Primary symptoms of caffeine intoxication[136]

Consumption of 1–1.5 grams (1,000–1,500 mg) per day is associated with a condition known as caffeinism.[137] Caffeinism usually combines caffeine dependency with a wide range of unpleasant symptoms including nervousness, irritability, restlessness, insomnia, headaches, and palpitations after caffeine use.[138]

Caffeine overdose can result in a state of central nervous system overstimulation known as caffeine intoxication, a clinically significant temporary condition that develops during, or shortly after, the consumption of caffeine.[139] This syndrome typically occurs only after ingestion of large amounts of caffeine, well over the amounts found in typical caffeinated beverages and caffeine tablets (e.g., more than 400–500 mg at a time). According to the DSM-5, caffeine intoxication may be diagnosed if five (or more) of the following symptoms develop after recent consumption of caffeine: restlessness, nervousness, excitement, insomnia, flushed face, diuresis, gastrointestinal disturbance, muscle twitching, rambling flow of thought and speech, tachycardia or cardiac arrhythmia, periods of inexhaustibility, and psychomotor agitation.[140]

According to the International Classification of Diseases (ICD-11), cases of very high caffeine intake (e.g. > 5 g) may result in caffeine intoxication with symptoms including mania, depression, lapses in judgment, disorientation, disinhibition, delusions, hallucinations or psychosis, and rhabdomyolysis.[139]

Energy drinks

High caffeine consumption in energy drinks (at least 1 liter or 320 mg of caffeine) was associated with short-term cardiovascular side effects including hypertension, prolonged QT interval, and heart palpitations. These cardiovascular side effects were not seen with smaller amounts of caffeine consumption in energy drinks (less than 200 mg).[79]

Severe intoxication

As of 2007 there is no known antidote or reversal agent for caffeine intoxication. Treatment of mild caffeine intoxication is directed toward symptom relief; severe intoxication may require peritoneal dialysis, hemodialysis, or hemofiltration.[136][141][142] Intralipid infusion therapy is indicated in cases of imminent risk of cardiac arrest in order to scavenge the free serum caffeine.[142]

Lethal dose

Death from caffeine ingestion appears to be rare, and most commonly caused by an intentional overdose of medications.[143] In 2016, 3702 caffeine-related exposures were reported to Poison Control Centers in the United States, of which 846 required treatment at a medical facility, and 16 had a major outcome; and several caffeine-related deaths are reported in case studies.[143] The LD50 of caffeine in rats is 192 milligrams per kilogram, the fatal dose in humans is estimated to be 150–200 milligrams per kilogram (2.2 lb) of body mass (75–100 cups of coffee for a 70 kg (150 lb) adult).[144][145] There are cases where doses as low as 57 milligrams per kilogram have been fatal.[146] A number of fatalities have been caused by overdoses of readily available powdered caffeine supplements, for which the estimated lethal amount is less than a tablespoon.[147] The lethal dose is lower in individuals whose ability to metabolize caffeine is impaired due to genetics or chronic liver disease.[148] A death was reported in 2013 of a man with liver cirrhosis who overdosed on caffeinated mints.[149][150]


Caffeine is a substrate for CYP1A2, and interacts with many substances through this and other mechanisms.[151]


According to DSST, alcohol provides a reduction in performance and caffeine has a significant improvement in performance.[152] When alcohol and caffeine are consumed jointly, the effects produced by caffeine are affected, but the alcohol effects remain the same.[153] For example, when additional caffeine is added, the drug effect produced by alcohol is not reduced.[153] However, the jitteriness and alertness given by caffeine is decreased when additional alcohol is consumed.[153] Alcohol consumption alone reduces both inhibitory and activational aspects of behavioral control. Caffeine antagonizes the activational aspect of behavioral control, but has no effect on the inhibitory behavioral control.[154] The Dietary Guidelines for Americans recommend avoidance of concomitant consumption of alcohol and caffeine, as this may lead to increased alcohol consumption, with a higher risk of alcohol-associated injury.


Smoking tobacco increases caffeine clearance by 56%.[155] Cigarette smoking induces the cytochrome P450 1A2 enzyme that breaks down caffeine, which may lead to increased caffeine tolerance and coffee consumption for regular smokers.[156]

Birth control

Birth control pills can extend the half-life of caffeine, requiring greater attention to caffeine consumption.[157]


Caffeine sometimes increases the effectiveness of some medications, such as those for headaches.[158] Caffeine was determined to increase the potency of some over-the-counter analgesic medications by 40%.[159]

The pharmacological effects of adenosine may be blunted in individuals taking large quantities of methylxanthines like caffeine.[160] Some other examples of methylxanthines include the medications theophylline and aminophylline, which are prescribed to relieve symptoms of asthma or COPD.[161]



Structure of a typical chemical synapse
Two skeletal formulas: left – caffeine, right – adenosine.
Caffeine's primary mechanism of action is as an adenosine receptor antagonist in the brain.

In the absence of caffeine and when a person is awake and alert, little adenosine is present in CNS neurons. With a continued wakeful state, over time adenosine accumulates in the neuronal synapse, in turn binding to and activating adenosine receptors found on certain CNS neurons; when activated, these receptors produce a cellular response that ultimately increases drowsiness. When caffeine is consumed, it antagonizes adenosine receptors; in other words, caffeine prevents adenosine from activating the receptor by blocking the location on the receptor where adenosine binds to it. As a result, caffeine temporarily prevents or relieves drowsiness, and thus maintains or restores alertness.[8]

Receptor and ion channel targets

Caffeine is an antagonist of adenosine A2A receptors, and knockout mouse studies have specifically implicated antagonism of the A2A receptor as responsible for the wakefulness-promoting effects of caffeine.[162] Antagonism of A2A receptors in the ventrolateral preoptic area (VLPO) reduces inhibitory GABA neurotransmission to the tuberomammillary nucleus, a histaminergic projection nucleus that activation-dependently promotes arousal.[163] This disinhibition of the tuberomammillary nucleus is the downstream mechanism by which caffeine produces wakefulness-promoting effects.[163] Caffeine is an antagonist of all four adenosine receptor subtypes (A1, A2A, A2B, and A3), although with varying potencies.[8][162] The affinity (KD) values of caffeine for the human adenosine receptors are 12 μM at A1, 2.4 μM at A2A, 13 μM at A2B, and 80 μM at A3.[162]

Antagonism of adenosine receptors by caffeine also stimulates the medullary vagal, vasomotor, and respiratory centers, which increases respiratory rate, reduces heart rate, and constricts blood vessels.[8] Adenosine receptor antagonism also promotes neurotransmitter release (e.g., monoamines and acetylcholine), which endows caffeine with its stimulant effects;[8][164] adenosine acts as an inhibitory neurotransmitter that suppresses activity in the central nervous system. Heart palpitations are caused by blockade of the A1 receptor.[8]

Because caffeine is both water- and lipid-soluble, it readily crosses the blood–brain barrier that separates the bloodstream from the interior of the brain. Once in the brain, the principal mode of action is as a nonselective antagonist of adenosine receptors (in other words, an agent that reduces the effects of adenosine). The caffeine molecule is structurally similar to adenosine, and is capable of binding to adenosine receptors on the surface of cells without activating them, thereby acting as a competitive antagonist.[165]

In addition to its activity at adenosine receptors, caffeine is an inositol trisphosphate receptor 1 antagonist and a voltage-independent activator of the ryanodine receptors (RYR1, RYR2, and RYR3).[166] It is also a competitive antagonist of the ionotropic glycine receptor.[167]

Effects on striatal dopamine

While caffeine does not directly bind to any dopamine receptors, it influences the binding activity of dopamine at its receptors in the striatum by binding to adenosine receptors that have formed GPCR heteromers with dopamine receptors, specifically the A1–D1 receptor heterodimer (this is a receptor complex with 1 adenosine A1 receptor and 1 dopamine D1 receptor) and the A2A–D2 receptor heterotetramer (this is a receptor complex with 2 adenosine A2A receptors and 2 dopamine D2 receptors).[168][169][170][171] The A2A–D2 receptor heterotetramer has been identified as a primary pharmacological target of caffeine, primarily because it mediates some of its psychostimulant effects and its pharmacodynamic interactions with dopaminergic psychostimulants.[169][170][171]

Caffeine also causes the release of dopamine in the dorsal striatum and nucleus accumbens core (a substructure within the ventral striatum), but not the nucleus accumbens shell, by antagonizing A1 receptors in the axon terminal of dopamine neurons and A1–A2A heterodimers (a receptor complex composed of 1 adenosine A1 receptor and 1 adenosine A2A receptor) in the axon terminal of glutamate neurons.[168][163] During chronic caffeine use, caffeine-induced dopamine release within the nucleus accumbens core is markedly reduced due to drug tolerance.[168][163]

Enzyme targets

Caffeine, like other xanthines, also acts as a phosphodiesterase inhibitor.[172] As a competitive nonselective phosphodiesterase inhibitor,[173] caffeine raises intracellular cyclic AMP, activates protein kinase A, inhibits TNF-alpha[174][175] and leukotriene[176] synthesis, and reduces inflammation and innate immunity.[176] Caffeine also affects the cholinergic system where it is a moderate inhibitor of the enzyme acetylcholinesterase.[177][178]


A diagram featuring 4 skeletal chemical formulas. Top (caffeine) relates to similar compounds paraxanthine, theobromine and theophylline.
Caffeine is metabolized in the liver via a single demethylation, resulting in three primary metabolites, paraxanthine (84%), theobromine (12%), and theophylline (4%), depending on which methyl group is removed.
Urinary metabolites of caffeine in humans at 48 hours post-dose[179]

Caffeine from coffee or other beverages is absorbed by the small intestine within 45 minutes of ingestion and distributed throughout all bodily tissues.[180] Peak blood concentration is reached within 1–2 hours.[181] It is eliminated by first-order kinetics.[182] Caffeine can also be absorbed rectally, evidenced by suppositories of ergotamine tartrate and caffeine (for the relief of migraine)[183] and of chlorobutanol and caffeine (for the treatment of hyperemesis).[184] However, rectal absorption is less efficient than oral: the maximum concentration (Cmax) and total amount absorbed (AUC) are both about 30% (i.e., 1/3.5) of the oral amounts.[185]

Caffeine's biological half-life – the time required for the body to eliminate one-half of a dose – varies widely among individuals according to factors such as pregnancy, other drugs, liver enzyme function level (needed for caffeine metabolism) and age. In healthy adults, caffeine's half-life is between 3 and 7 hours.[8] The half-life is decreased by 30-50% in adult male smokers, approximately doubled in women taking oral contraceptives, and prolonged in the last trimester of pregnancy.[126] In newborns the half-life can be 80 hours or more, dropping very rapidly with age, possibly to less than the adult value by age 6 months.[126] The antidepressant fluvoxamine (Luvox) reduces the clearance of caffeine by more than 90%, and increases its elimination half-life more than tenfold; from 4.9 hours to 56 hours.[186]

Caffeine is metabolized in the liver by the cytochrome P450 oxidase enzyme system, in particular, by the CYP1A2 isozyme, into three dimethylxanthines,[187] each of which has its own effects on the body:

1,3,7-Trimethyluric acid is a minor caffeine metabolite.[8] 7-Methylxanthine is also a metabolite of caffeine.[188][189] Each of the above metabolites is further metabolized and then excreted in the urine. Caffeine can accumulate in individuals with severe liver disease, increasing its half-life.[190]

A 2011 review found that increased caffeine intake was associated with a variation in two genes that increase the rate of caffeine catabolism. Subjects who had this mutation on both chromosomes consumed 40 mg more caffeine per day than others.[191] This is presumably due to the need for a higher intake to achieve a comparable desired effect, not that the gene led to a disposition for greater incentive of habituation.


Pure anhydrous caffeine is a bitter-tasting, white, odorless powder with a melting point of 235–238 °C.[10][11] Caffeine is moderately soluble in water at room temperature (2 g/100 mL), but very soluble in boiling water (66 g/100 mL).[192] It is also moderately soluble in ethanol (1.5 g/100 mL).[192] It is weakly basic (pKa of conjugate acid = ~0.6) requiring strong acid to protonate it.[193] Caffeine does not contain any stereogenic centers[194] and hence is classified as an achiral molecule.[195]

The xanthine core of caffeine contains two fused rings, a pyrimidinedione and imidazole. The pyrimidinedione in turn contains two amide functional groups that exist predominantly in a zwitterionic resonance the location from which the nitrogen atoms are double bonded to their adjacent amide carbons atoms. Hence all six of the atoms within the pyrimidinedione ring system are sp2 hybridized and planar. The imidazole ring also has a resonance. Therefore, the fused 5,6 ring core of caffeine contains a total of ten pi electrons and hence according to Hückel's rule is aromatic.[196]


File:Caffeine biosynthesis.tif

The biosynthesis of caffeine is an example of convergent evolution among different species.[201][202][203]

Caffeine may be synthesized in the lab starting with dimethylurea and malonic acid.[clarification needed][199][200][204]

Commercial supplies of caffeine are not usually manufactured synthetically because the chemical is readily available as a byproduct of decaffeination.[205]


Main page: Chemistry:Decaffeination
Fibrous crystals of purified caffeine. Dark-field microscopy image, about 7 mm × 11 mm.

Extraction of caffeine from coffee, to produce caffeine and decaffeinated coffee, can be performed using a number of solvents. Following are main methods:

  • Water extraction: Coffee beans are soaked in water. The water, which contains many other compounds in addition to caffeine and contributes to the flavor of coffee, is then passed through activated charcoal, which removes the caffeine. The water can then be put back with the beans and evaporated dry, leaving decaffeinated coffee with its original flavor. Coffee manufacturers recover the caffeine and resell it for use in soft drinks and over-the-counter caffeine tablets.[206]
  • Supercritical carbon dioxide extraction: Supercritical carbon dioxide is an excellent nonpolar solvent for caffeine, and is safer than the organic solvents that are otherwise used. The extraction process is simple: CO
    is forced through the green coffee beans at temperatures above 31.1 °C and pressures above 73 atm. Under these conditions, CO
    is in a "supercritical" state: It has gaslike properties that allow it to penetrate deep into the beans but also liquid-like properties that dissolve 97–99% of the caffeine. The caffeine-laden CO
    is then sprayed with high-pressure water to remove the caffeine. The caffeine can then be isolated by charcoal adsorption (as above) or by distillation, recrystallization, or reverse osmosis.[206]
  • Extraction by organic solvents: Certain organic solvents such as ethyl acetate present much less health and environmental hazard than chlorinated and aromatic organic solvents used formerly. Another method is to use triglyceride oils obtained from spent coffee grounds.[206]

"Decaffeinated" coffees do in fact contain caffeine in many cases – some commercially available decaffeinated coffee products contain considerable levels. One study found that decaffeinated coffee contained 10 mg of caffeine per cup, compared to approximately 85 mg of caffeine per cup for regular coffee.[207]

Detection in body fluids

Caffeine can be quantified in blood, plasma, or serum to monitor therapy in neonates, confirm a diagnosis of poisoning, or facilitate a medicolegal death investigation. Plasma caffeine levels are usually in the range of 2–10 mg/L in coffee drinkers, 12–36 mg/L in neonates receiving treatment for apnea, and 40–400 mg/L in victims of acute overdosage. Urinary caffeine concentration is frequently measured in competitive sports programs, for which a level in excess of 15 mg/L is usually considered to represent abuse.[208]


Some analog substances have been created which mimic caffeine's properties with either function or structure or both. Of the latter group are the xanthines DMPX[209] and 8-chlorotheophylline, which is an ingredient in dramamine. Members of a class of nitrogen substituted xanthines are often proposed as potential alternatives to caffeine.[210] Many other xanthine analogues constituting the adenosine receptor antagonist class have also been elucidated.[211]

Some other caffeine analogs:

Precipitation of tannins

Caffeine, as do other alkaloids such as cinchonine, quinine or strychnine, precipitates polyphenols and tannins. This property can be used in a quantitation method.[clarification needed][212]

Natural occurrence

Roasted coffee beans

Around thirty plant species are known to contain caffeine.[213] Common sources are the "beans" (seeds) of the two cultivated coffee plants, Coffea arabica and Coffea canephora (the quantity varies, but 1.3% is a typical value); and of the cocoa plant, Theobroma cacao; the leaves of the tea plant; and kola nuts. Other sources include the leaves of yaupon holly, South American holly yerba mate, and Amazonian holly guayusa; and seeds from Amazonian maple guarana berries. Temperate climates around the world have produced unrelated caffeine-containing plants.

Caffeine in plants acts as a natural pesticide: it can paralyze and kill predator insects feeding on the plant.[214] High caffeine levels are found in coffee seedlings when they are developing foliage and lack mechanical protection.[215] In addition, high caffeine levels are found in the surrounding soil of coffee seedlings, which inhibits seed germination of nearby coffee seedlings, thus giving seedlings with the highest caffeine levels fewer competitors for existing resources for survival.[216] Caffeine is stored in tea leaves in two places. Firstly, in the cell vacuoles where it is complexed with polyphenols. This caffeine probably is released into the mouth parts of insects, to discourage herbivory. Secondly, around the vascular bundles, where it probably inhibits pathogenic fungi from entering and colonizing the vascular bundles.[217] Caffeine in nectar may improve the reproductive success of the pollen producing plants by enhancing the reward memory of pollinators such as honey bees.[20]

The differing perceptions in the effects of ingesting beverages made from various plants containing caffeine could be explained by the fact that these beverages also contain varying mixtures of other methylxanthine alkaloids, including the cardiac stimulants theophylline and theobromine, and polyphenols that can form insoluble complexes with caffeine.[218]


Caffeine content in select food and drugs[219][220][221][222][223]
Product Serving size Caffeine per serving (mg) Caffeine (mg/L)
Caffeine tablet (regular-strength) 1 tablet 100
Caffeine tablet (extra-strength) 1 tablet 200
Excedrin tablet 1 tablet 65
Hershey's Special Dark (45% cacao content) 1 bar (43 g or 1.5 oz) 31
Hershey's Milk Chocolate (11% cacao content) 1 bar (43 g or 1.5 oz) 10
Percolated coffee 207 mL (7.0 US fl oz) 80–135 386–652
Drip coffee 207 mL (7.0 US fl oz) 115–175 555–845
Coffee, decaffeinated 207 mL (7.0 US fl oz) 5–15 24–72
Coffee, espresso 44–60 mL (1.5–2.0 US fl oz) 100 1,691–2,254
Tea – black, green, and other types, – steeped for 3 min. 177 millilitres (6.0 US fl oz) 22–74[222][223] 124–418
Guayakí yerba mate (loose leaf) 6 g (0.21 oz) 85[224] approx. 358
Coca-Cola 355 mL (12.0 US fl oz) 34 96
Mountain Dew 355 mL (12.0 US fl oz) 54 154
Pepsi Zero Sugar 355 mL (12.0 US fl oz) 69 194
Guaraná Antarctica 350 mL (12 US fl oz) 30 100
Jolt Cola 695 mL (23.5 US fl oz) 280 403
Red Bull 250 mL (8.5 US fl oz) 80 320
Coffee-flavored milk drink 250 mL (8.5 US fl oz) 33–197[225] 660–3290[225]

Products containing caffeine include coffee, tea, soft drinks ("colas"), energy drinks, other beverages, chocolate,[226] caffeine tablets, other oral products, and inhalation products. According to a 2020 study in the United States, coffee is the major source of caffeine intake in middle-aged adults, while soft drinks and tea are the major sources in adolescents.[79] Energy drinks are more commonly consumed as a source of caffeine in adolescents as compared to adults.[79]



The world's primary source of caffeine is the coffee "bean" (the seed of the coffee plant), from which coffee is brewed. Caffeine content in coffee varies widely depending on the type of coffee bean and the method of preparation used;[227] even beans within a given bush can show variations in concentration. In general, one serving of coffee ranges from 80 to 100 milligrams, for a single shot (30 milliliters) of arabica-variety espresso, to approximately 100–125 milligrams for a cup (120 milliliters) of drip coffee.[228][229] Arabica coffee typically contains half the caffeine of the robusta variety.[227] In general, dark-roast coffee has very slightly less caffeine than lighter roasts because the roasting process reduces caffeine content of the bean by a small amount.[228][229]


Tea contains more caffeine than coffee by dry weight. A typical serving, however, contains much less, since less of the product is used as compared to an equivalent serving of coffee. Also contributing to caffeine content are growing conditions, processing techniques, and other variables. Thus, teas contain varying amounts of caffeine.[230]

Tea contains small amounts of theobromine and slightly higher levels of theophylline than coffee. Preparation and many other factors have a significant impact on tea, and color is a very poor indicator of caffeine content. Teas like the pale Japanese green tea, gyokuro, for example, contain far more caffeine than much darker teas like lapsang souchong, which has very little.[230]

Soft drinks and energy drinks

Caffeine is also a common ingredient of soft drinks, such as cola, originally prepared from kola nuts. Soft drinks typically contain 0 to 55 milligrams of caffeine per 12 ounce serving.[231] By contrast, energy drinks, such as Red Bull, can start at 80 milligrams of caffeine per serving. The caffeine in these drinks either originates from the ingredients used or is an additive derived from the product of decaffeination or from chemical synthesis. Guarana, a prime ingredient of energy drinks, contains large amounts of caffeine with small amounts of theobromine and theophylline in a naturally occurring slow-release excipient.[232]

Other beverages

  • Mate is a drink popular in many parts of South America. Its preparation consists of filling a gourd with the leaves of the South American holly yerba mate, pouring hot but not boiling water over the leaves, and drinking with a straw, the bombilla, which acts as a filter so as to draw only the liquid and not the yerba leaves.[233]
  • Guaraná is a soft drink originating in Brazil made from the seeds of the Guaraná fruit.
  • The leaves of Ilex guayusa, the Ecuadorian holly tree, are placed in boiling water to make a guayusa tea.[234]
  • The leaves of Ilex vomitoria, the yaupon holly tree, are placed in boiling water to make a yaupon tea.
  • Commercially prepared coffee-flavoured milk beverages are popular in Australia.[235] Examples include Oak's Ice Coffee and Farmers Union Iced Coffee. The amount of caffeine in these beverages can vary widely. Caffeine concentrations can differ significantly from the manufacturer's claims.[225]


Chocolate derived from cocoa beans contains a small amount of caffeine. The weak stimulant effect of chocolate may be due to a combination of theobromine and theophylline, as well as caffeine.[236] A typical 28-gram serving of a milk chocolate bar has about as much caffeine as a cup of decaffeinated coffee. By weight, dark chocolate has one to two times the amount of caffeine as coffee: 80–160 mg per 100 g. Higher percentages of cocoa such as 90% amount to 200 mg per 100 g approximately and thus, a 100-gram 85% cocoa chocolate bar contains about 195 mg caffeine.[220]


No-Doz 100 mg caffeine tablets

Tablets offer several advantages over coffee, tea, and other caffeinated beverages, including convenience, known dosage, and avoidance of concomitant intake of sugar, acids, and fluids. A use of caffeine in this form is said to improve mental alertness.[237] These tablets are commonly used by students studying for their exams and by people who work or drive for long hours.[238]

Other oral products

One U.S. company is marketing oral dissolvable caffeine strips.[239] Another intake route is SpazzStick, a caffeinated lip balm.[240] Alert Energy Caffeine Gum was introduced in the United States in 2013, but was voluntarily withdrawn after an announcement of an investigation by the FDA of the health effects of added caffeine in foods.[241]


There are several products being marketed that offer inhalers that deliver proprietary blends of supplements, with caffeine being a key ingredient.[242] In 2012, the FDA sent a warning letter to one of the companies marketing these inhalers, expressing concerns for the lack of safety information available about inhaled caffeine.[243]

Combinations with other drugs

  • Some beverages combine alcohol with caffeine to create a caffeinated alcoholic drink. The stimulant effects of caffeine may mask the depressant effects of alcohol, potentially reducing the user's awareness of their level of intoxication. Such beverages have been the subject of bans due to safety concerns. In particular, the United States Food and Drug Administration has classified caffeine added to malt liquor beverages as an "unsafe food additive".[244]
  • Ya ba contains a combination of methamphetamine and caffeine.
  • Painkillers such as propyphenazone/paracetamol/caffeine combine caffeine with an analgesic.


Discovery and spread of use

An old photo of a dozen old and middle-aged men sitting on the ground around a mat. A man in front sits next to a mortar and holds a bat, ready for grinding. A man opposite to him holds a long spoon.
Coffeehouse in Palestine, c. 1900

According to Chinese legend, the Chinese emperor Shennong, reputed to have reigned in about 3000 BCE, inadvertently discovered tea when he noted that when certain leaves fell into boiling water, a fragrant and restorative drink resulted.[245] Shennong is also mentioned in Lu Yu's Cha Jing, a famous early work on the subject of tea.[246]

The earliest credible evidence of either coffee drinking or knowledge of the coffee plant appears in the middle of the fifteenth century, in the Sufi monasteries of the Yemen in southern Arabia.[247] From Mocha, coffee spread to Egypt and North Africa, and by the 16th century, it had reached the rest of the Middle East, Persia and Turkey. From the Middle East, coffee drinking spread to Italy, then to the rest of Europe, and coffee plants were transported by the Dutch to the East Indies and to the Americas.[248]

Kola nut use appears to have ancient origins. It is chewed in many West African cultures, in both private and social settings, to restore vitality and ease hunger pangs.

The earliest evidence of cocoa bean use comes from residue found in an ancient Mayan pot dated to 600 BCE. Also, chocolate was consumed in a bitter and spicy drink called xocolatl, often seasoned with vanilla, chile pepper, and achiote. Xocolatl was believed to fight fatigue, a belief probably attributable to the theobromine and caffeine content. Chocolate was an important luxury good throughout pre-Columbian Mesoamerica, and cocoa beans were often used as currency.[249]

Xocolatl was introduced to Europe by the Spaniards, and became a popular beverage by 1700. The Spaniards also introduced the cacao tree into the West Indies[250] and the Philippines .[251]

The leaves and stems of the yaupon holly (Ilex vomitoria) were used by Native Americans to brew a tea called asi or the "black drink".[252] Archaeologists have found evidence of this use far into antiquity,[253] possibly dating to Late Archaic times.[252]

Chemical identification, isolation, and synthesis

Pierre Joseph Pelletier

In 1819, the German chemist Friedlieb Ferdinand Runge isolated relatively pure caffeine for the first time; he called it "Kaffebase" (i.e., a base that exists in coffee).[254] According to Runge, he did this at the behest of Johann Wolfgang von Goethe.[lower-alpha 1][256] In 1821, caffeine was isolated both by the French chemist Pierre Jean Robiquet and by another pair of French chemists, Pierre-Joseph Pelletier and Joseph Bienaimé Caventou, according to Swedish chemist Jöns Jacob Berzelius in his yearly journal. Furthermore, Berzelius stated that the French chemists had made their discoveries independently of any knowledge of Runge's or each other's work.[257] However, Berzelius later acknowledged Runge's priority in the extraction of caffeine, stating:[258] "However, at this point, it should not remain unmentioned that Runge (in his Phytochemical Discoveries, 1820, pages 146–147) specified the same method and described caffeine under the name Caffeebase a year earlier than Robiquet, to whom the discovery of this substance is usually attributed, having made the first oral announcement about it at a meeting of the Pharmacy Society in Paris."

Pelletier's article on caffeine was the first to use the term in print (in the French form Caféine from the French word for coffee: café).[259] It corroborates Berzelius's account:

Caffeine, noun (feminine). Crystallizable substance discovered in coffee in 1821 by Mr. Robiquet. During the same period – while they were searching for quinine in coffee because coffee is considered by several doctors to be a medicine that reduces fevers and because coffee belongs to the same family as the cinchona [quinine] tree – on their part, Messrs. Pelletier and Caventou obtained caffeine; but because their research had a different goal and because their research had not been finished, they left priority on this subject to Mr. Robiquet. We do not know why Mr. Robiquet has not published the analysis of coffee which he read to the Pharmacy Society. Its publication would have allowed us to make caffeine better known and give us accurate ideas of coffee's composition ...

Robiquet was one of the first to isolate and describe the properties of pure caffeine,[260] whereas Pelletier was the first to perform an elemental analysis.[261]

In 1827, M. Oudry isolated "théine" from tea,[262] but in 1838 it was proved by Mulder[263] and by Carl Jobst[264] that theine was actually the same as caffeine.

In 1895, German chemist Hermann Emil Fischer (1852–1919) first synthesized caffeine from its chemical components (i.e. a "total synthesis"), and two years later, he also derived the structural formula of the compound.[265] This was part of the work for which Fischer was awarded the Nobel Prize in 1902.[266]

Historic regulations

Because it was recognized that coffee contained some compound that acted as a stimulant, first coffee and later also caffeine has sometimes been subject to regulation. For example, in the 16th century Islamists in Mecca and in the Ottoman Empire made coffee illegal for some classes.[267][268][269] Charles II of England tried to ban it in 1676,[270][271] Frederick II of Prussia banned it in 1777,[272][273] and coffee was banned in Sweden at various times between 1756 and 1823.

In 1911, caffeine became the focus of one of the earliest documented health scares, when the US government seized 40 barrels and 20 kegs of Coca-Cola syrup in Chattanooga, Tennessee, alleging the caffeine in its drink was "injurious to health".[274] Although the Supreme Court later ruled in favor of Coca-Cola in United States v. Forty Barrels and Twenty Kegs of Coca-Cola, two bills were introduced to the U.S. House of Representatives in 1912 to amend the Pure Food and Drug Act, adding caffeine to the list of "habit-forming" and "deleterious" substances, which must be listed on a product's label.[275]

Society and culture


United States

The Food and Drug Administration (FDA) in the United States currently allows only beverages containing less than 0.02% caffeine;[276] but caffeine powder, which is sold as a dietary supplement, is unregulated.[277] It is a regulatory requirement that the label of most prepackaged foods must declare a list of ingredients, including food additives such as caffeine, in descending order of proportion. However, there is no regulatory provision for mandatory quantitative labeling of caffeine, (e.g., milligrams caffeine per stated serving size). There are a number of food ingredients that naturally contain caffeine. These ingredients must appear in food ingredient lists. However, as is the case for "food additive caffeine", there is no requirement to identify the quantitative amount of caffeine in composite foods containing ingredients that are natural sources of caffeine. While coffee or chocolate are broadly recognized as caffeine sources, some ingredients (e.g., guarana, yerba maté) are likely less recognized as caffeine sources. For these natural sources of caffeine, there is no regulatory provision requiring that a food label identify the presence of caffeine nor state the amount of caffeine present in the food.[278]


Global consumption of caffeine has been estimated at 120,000 tonnes per year, making it the world's most popular psychoactive substance.[22] This amounts to an average of one serving of a caffeinated beverage for every person every day.[22] The consumption of caffeine has remained stable between 1997 and 2015.[279] Coffee, tea and soft drinks are the most important caffeine sources, with energy drinks contributing little to the total caffeine intake across all age groups.[279]


Until recently, the Seventh-day Adventist Church asked for its members to "abstain from caffeinated drinks", but has removed this from baptismal vows (while still recommending abstention as policy).[280] Some from these religions believe that one is not supposed to consume a non-medical, psychoactive substance, or believe that one is not supposed to consume a substance that is addictive. The Church of Jesus Christ of Latter-day Saints has said the following with regard to caffeinated beverages: "... the Church revelation spelling out health practices (Doctrine and Covenants 89) does not mention the use of caffeine. The Church's health guidelines prohibit alcoholic drinks, smoking or chewing of tobacco, and 'hot drinks' – taught by Church leaders to refer specifically to tea and coffee."[281]

Gaudiya Vaishnavas generally also abstain from caffeine, because they believe it clouds the mind and overstimulates the senses.[282] To be initiated under a guru, one must have had no caffeine, alcohol, nicotine or other drugs, for at least a year.[283]

Caffeinated beverages are widely consumed by Muslims today. In the 16th century, some Muslim authorities made unsuccessful attempts to ban them as forbidden "intoxicating beverages" under Islamic dietary laws.[284][285]

Other organisms

Caffeine effects on spider webs
Caffeine effects on spider webs

Recently discovered bacteria Pseudomonas putida CBB5 can live on pure caffeine and can cleave caffeine into carbon dioxide and ammonia.[286]

Caffeine is toxic to birds[287] and to dogs and cats,[288] and has a pronounced adverse effect on mollusks, various insects, and spiders.[289] This is at least partly due to a poor ability to metabolize the compound, causing higher levels for a given dose per unit weight.[179] Caffeine has also been found to enhance the reward memory of honey bees.[20]


Caffeine has been used to double chromosomes in haploid wheat.[290]

See also


  1. In 1819, Runge was invited to show Goethe how belladonna caused dilation of the pupil, which Runge did, using a cat as an experimental subject. Goethe was so impressed with the demonstration that:
    Nachdem Goethe mir seine größte Zufriedenheit sowol über die Erzählung des durch scheinbaren schwarzen Staar Geretteten, wie auch über das andere ausgesprochen, übergab er mir noch eine Schachtel mit Kaffeebohnen, die ein Grieche ihm als etwas Vorzügliches gesandt. "Auch diese können Sie zu Ihren Untersuchungen brauchen," sagte Goethe. Er hatte recht; denn bald darauf entdeckte ich darin das, wegen seines großen Stickstoffgehaltes so berühmt gewordene Coffein.
    ("After Goethe had expressed to me his greatest satisfaction regarding the account of the man [whom I'd] rescued [from serving in Napoleon's army] by apparent "black star" [i.e., amaurosis, blindness] as well as the other, he handed me a carton of coffee beans, which a Greek had sent him as a delicacy. 'You can also use these in your investigations,' said Goethe. He was right; for soon thereafter I discovered therein caffeine, which became so famous on account of its high nitrogen content.").[255]
  1. "Caffeine". 
  2. 2.0 2.1 2.2 2.3 2.4 Cite error: Invalid <ref> tag; no text was provided for refs named Nestler caffeine dependence-addiction
  3. 3.0 3.1 Karch's pathology of drug abuse (4th ed.). Boca Raton: CRC Press. 2009. pp. 229–230. ISBN 978-0-8493-7881-2. "The suggestion has also been made that a caffeine dependence syndrome exists ... In one controlled study, dependence was diagnosed in 16 of 99 individuals who were evaluated. The median daily caffeine consumption of this group was only 357 mg per day (Strain et al., 1994).
    Since this observation was first published, caffeine addiction has been added as an official diagnosis in ICDM 9. This decision is disputed by many and is not supported by any convincing body of experimental evidence. ... All of these observations strongly suggest that caffeine does not act on the dopaminergic structures related to addiction, nor does it improve performance by alleviating any symptoms of withdrawal"
  4. 4.0 4.1 Cite error: Invalid <ref> tag; no text was provided for refs named DSM-5 definitions + addiction-dependence distinction + Caffeine use disorder
  5. Cite error: Invalid <ref> tag; no text was provided for refs named CRC Press
  6. 6.0 6.1 6.2 "A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features". Psychopharmacology 176 (1): 1–29. October 2004. doi:10.1007/s00213-004-2000-x. PMID 15448977. "Results: Of 49 symptom categories identified, the following 10 fulfilled validity criteria: headache, fatigue, decreased energy/ activeness, decreased alertness, drowsiness, decreased contentedness, depressed mood, difficulty concentrating, irritability, and foggy/not clearheaded. In addition, flu-like symptoms, nausea/vomiting, and muscle pain/stiffness were judged likely to represent valid symptom categories. In experimental studies, the incidence of headache was 50% and the incidence of clinically significant distress or functional impairment was 13%. Typically, onset of symptoms occurred 12–24 h after abstinence, with peak intensity at 20–51 h, and for a duration of 2–9 days.". 
  7. 7.0 7.1 7.2 7.3 "Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice". Pharmacological Reports 68 (1): 56–61. February 2016. doi:10.1016/j.pharep.2015.06.138. PMID 26721352. 
  8. 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 8.10 8.11 8.12 8.13 8.14 8.15 "Caffeine". University of Alberta. 16 September 2013. 
  9. Institute of Medicine (US) Committee on Military Nutrition Research (2001). "2, Pharmacology of Caffeine" (in en). Pharmacology of Caffeine. National Academies Press (US). 
  10. 10.0 10.1 "Caffeine". NCBI. "
    Boiling Point
    178 °C (sublimes)
    Melting Point
    238 DEG C (ANHYD)"
  11. 11.0 11.1 "Caffeine". Royal Society of Chemistry. "Experimental Melting Point:
    234–236 °C Alfa Aesar
    237 °C Oxford University Chemical Safety Data
    238 °C LKT Labs [C0221]
    237 °C Jean-Claude Bradley Open Melting Point Dataset 14937
    238 °C Jean-Claude Bradley Open Melting Point Dataset 17008, 17229, 22105, 27892, 27893, 27894, 27895
    235.25 °C Jean-Claude Bradley Open Melting Point Dataset 27892, 27893, 27894, 27895
    236 °C Jean-Claude Bradley Open Melting Point Dataset 27892, 27893, 27894, 27895
    235 °C Jean-Claude Bradley Open Melting Point Dataset 6603
    234–236 °C Alfa Aesar A10431, 39214
    Experimental Boiling Point:
    178 °C (Sublimes) Alfa Aesar
    178 °C (Sublimes) Alfa Aesar 39214"
  12. 12.0 12.1 "Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects". Brain Research. Brain Research Reviews 17 (2): 139–170. 1992. doi:10.1016/0165-0173(92)90012-B. PMID 1356551. 
  13. "Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis". Nutrition Reviews 72 (8): 507–522. August 2014. doi:10.1111/nure.12120. PMID 24946991. 
  14. "Psychostimulants and cognition: a continuum of behavioral and cognitive activation". Pharmacological Reviews 66 (1): 193–221. January 2014. doi:10.1124/pr.112.007054. PMID 24344115. 
  15. "Caffeine and adenosine". Journal of Alzheimer's Disease 20 (Suppl 1): S3-15. 2010. doi:10.3233/JAD-2010-1379. PMID 20164566. 
  16. Principles of Life (2 ed.). 2015. pp. 102–103. ISBN 978-1-4641-8652-3. 
  17. "The Medicinal Chemistry of Caffeine". Journal of Medicinal Chemistry 64 (11): 7156–7178. June 2021. doi:10.1021/acs.jmedchem.1c00261. PMID 34019396. 
  18. Encyclopedia of Food and Health. Elsevier Science. 2015. p. 561. ISBN 978-0-12-384953-3. Retrieved 17 June 2018. 
  19. The 100 Most Important Chemical Compounds: A Reference Guide. Greenwood Press. 2007. p. 55. ISBN 978-0-313-33758-1. Retrieved 17 June 2018. 
  20. 20.0 20.1 20.2 "Caffeine in floral nectar enhances a pollinator's memory of reward". Science 339 (6124): 1202–4. March 2013. doi:10.1126/science.1228806. PMID 23471406. Bibcode2013Sci...339.1202W. 
  21. "Global coffee consumption, 2020/21". 
  22. 22.0 22.1 22.2 "What's your poison: caffeine". Australian Broadcasting Corporation. 1997. 
  23. "The essence of commodification: caffeine dependencies in the early modern world". Journal of Social History 35 (2): 269–294. 2001. doi:10.1353/jsh.2001.0125. PMID 18546583. 
  24. WHO Model List of Essential Medicines (18th ed.). World Health Organization. October 2013. p. 34 [p. 38 of pdf]. Retrieved 23 December 2014. 
  25. "The impact of coffee on health". Maturitas 75 (1): 7–21. May 2013. doi:10.1016/j.maturitas.2013.02.002. PMID 23465359. 
  26. 26.0 26.1 "Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease". Geriatrics & Gerontology International 14 (2): 430–9. April 2014. doi:10.1111/ggi.12123. PMID 23879665. 
  27. "Effects of caffeine on sleep quality and daytime functioning". Risk Management and Healthcare Policy 11: 263–271. 7 December 2018. doi:10.2147/RMHP.S156404. PMID 30573997. 
  28. 28.0 28.1 28.2 "Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes". The Cochrane Database of Systematic Reviews (6): CD006965. June 2015. doi:10.1002/14651858.CD006965.pub4. PMID 26058966. 
  29. 29.0 29.1 American College of Obstetricians and Gynecologists (August 2010). "ACOG CommitteeOpinion No. 462: Moderate caffeine consumption during pregnancy". Obstetrics and Gynecology 116 (2 Pt 1): 467–8. doi:10.1097/AOG.0b013e3181eeb2a1. PMID 20664420. 
  30. "Tolerance to the humoral and hemodynamic effects of caffeine in man". The Journal of Clinical Investigation 67 (4): 1111–7. April 1981. doi:10.1172/JCI110124. PMID 7009653. 
  31. "Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters". Journal of Food Science 75 (3): R77–R87. April 2010. doi:10.1111/j.1750-3841.2010.01561.x. PMID 20492310. 
  32. "Scientific Opinion on the safety of caffeine". EFSA Journal 13 (5): 4102. 2015. doi:10.2903/j.efsa.2015.4102. 
  33. "Quantification of Caffeine and Chlorogenic Acid in Green and Roasted Coffee Samples Using HPLC-DAD and Evaluation of the Effect of Degree of Roasting on Their Levels". Molecules 26 (24): 7502. December 2021. doi:10.3390/molecules26247502. PMID 34946584. 
  34. "A comprehensive approach to the prevention of bronchopulmonary dysplasia". Pediatric Pulmonology 46 (12): 1153–65. December 2011. doi:10.1002/ppul.21508. PMID 21815280. 
  35. "Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial". Biology of the Neonate 88 (3): 208–13. 2005. doi:10.1159/000087584. PMID 16210843. 
  36. "Caffeine therapy for apnea of prematurity". The New England Journal of Medicine 354 (20): 2112–21. May 2006. doi:10.1056/NEJMoa054065. PMID 16707748. 
  37. "Long-term effects of caffeine therapy for apnea of prematurity". The New England Journal of Medicine 357 (19): 1893–902. November 2007. doi:10.1056/NEJMoa073679. PMID 17989382. 
  38. "Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity". JAMA 307 (3): 275–82. January 2012. doi:10.1001/jama.2011.2024. PMID 22253394. 
  39. "Losing sleep over the caffeination of prematurity". The Journal of Physiology 587 (Pt 22): 5299–300. November 2009. doi:10.1113/jphysiol.2009.182303. PMID 19915211. 
  40. "Apnea of prematurity: pathogenesis and management strategies". Journal of Perinatology 31 (5): 302–10. May 2011. doi:10.1038/jp.2010.126. PMID 21127467. 
  41. "Prophylactic methylxanthine for prevention of apnoea in preterm infants". The Cochrane Database of Systematic Reviews 2010 (12): CD000432. December 2010. doi:10.1002/14651858.CD000432.pub2. PMID 21154344. 
  42. 42.0 42.1 "Caffeine: Summary of Clinical Use". The International Union of Basic and Clinical Pharmacology. 
  43. "The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension". J. Neurol. 264 (8): 1567–1582. August 2017. doi:10.1007/s00415-016-8375-x. PMID 28050656. 
  44. "Orthostatic hypotension in the elderly: diagnosis and treatment". The American Journal of Medicine 120 (10): 841–7. October 2007. doi:10.1016/j.amjmed.2007.02.023. PMID 17904451. 
  45. 45.0 45.1 "Chronic coffee consumption and respiratory disease: A systematic review". The Clinical Respiratory Journal 12 (3): 1283–1294. March 2018. doi:10.1111/crj.12662. PMID 28671769. 
  46. 46.0 46.1 "Caffeine for asthma". The Cochrane Database of Systematic Reviews 2010 (1): CD001112. January 2010. doi:10.1002/14651858.CD001112.pub2. PMID 20091514. 
  47. "Caffeine as an analgesic adjuvant for acute pain in adults". The Cochrane Database of Systematic Reviews 2019 (12): CD009281. December 2014. doi:10.1002/14651858.cd009281.pub3. PMID 25502052. 
  48. "The effect of coffee/caffeine on postoperative ileus following elective colorectal surgery: a meta-analysis of randomized controlled trials". International Journal of Colorectal Disease 37 (3): 623–630. March 2022. doi:10.1007/s00384-021-04086-3. PMID 34993568. 
  49. "Caffeine as an Independent Variable in Behavioral Research: Trends from the Literature Specific to ADHD". Journal of Caffeine Research 5 (3): 95–104. 2015. doi:10.1089/jcr.2014.0032. 
  50. 50.0 50.1 "Considerations for ADHD in the child with epilepsy and the child with migraine". Expert Review of Neurotherapeutics 17 (9): 861–869. September 2017. doi:10.1080/14737175.2017.1360136. PMID 28749241. 
  51. "Review: Trends, Safety, and Recommendations for Caffeine Use in Children and Adolescents". Journal of the American Academy of Child and Adolescent Psychiatry 58 (1): 36–45. January 2019. doi:10.1016/j.jaac.2018.06.030. PMID 30577937. 
  52. 52.0 52.1 52.2 "Caffeine: Psychological Effects, Use and Abuse". Orthomolecular Psychiatry 10 (3): 202–211. 1981. 
  53. "Is caffeine a cognitive enhancer?". Journal of Alzheimer's Disease 20 (Suppl 1): S85–94. 2010. doi:10.3233/JAD-2010-091315. PMID 20182035. "Caffeine does not usually affect performance in learning and memory tasks, although caffeine may occasionally have facilitatory or inhibitory effects on memory and learning. Caffeine facilitates learning in tasks in which information is presented passively; in tasks in which material is learned intentionally, caffeine has no effect. Caffeine facilitates performance in tasks involving working memory to a limited extent, but hinders performance in tasks that heavily depend on this, and caffeine appears to improve memory performance under suboptimal alertness. Most studies, however, found improvements in reaction time. The ingestion of caffeine does not seem to affect long-term memory. ... Its indirect action on arousal, mood and concentration contributes in large part to its cognitive enhancing properties.". 
  54. "Effects of caffeine on sleep and cognition". Human Sleep and Cognition Part II - Clinical and Applied Research. Progress in Brain Research. 190. 2011. pp. 105–17. doi:10.1016/B978-0-444-53817-8.00006-2. ISBN 978-0-444-53817-8. 
  55. "Caffeine for the prevention of injuries and errors in shift workers". The Cochrane Database of Systematic Reviews 2010 (5): CD008508. May 2010. doi:10.1002/14651858.CD008508. PMID 20464765. 
  56. "A review of caffeine's effects on cognitive, physical and occupational performance". Neuroscience and Biobehavioral Reviews 71: 294–312. December 2016. doi:10.1016/j.neubiorev.2016.09.001. PMID 27612937. 
  57. 57.0 57.1 "Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis". Nutrition Reviews 72 (8): 507–22. August 2014. doi:10.1111/nure.12120. PMID 24946991. 
  58. 58.0 58.1 58.2 58.3 58.4 58.5 "The effects of caffeine, nicotine, ethanol, and tetrahydrocannabinol on exercise performance". Nutrition & Metabolism 10 (1): 71. December 2013. doi:10.1186/1743-7075-10-71. PMID 24330705.  Quote:
    Caffeine-induced increases in performance have been observed in aerobic as well as anaerobic sports (for reviews, see [26,30,31])...
  59. "Dietary supplements and team-sport performance". Sports Medicine 40 (12): 995–1017. December 2010. doi:10.2165/11536870-000000000-00000. PMID 21058748. 
  60. "Does caffeine added to carbohydrate provide additional ergogenic benefit for endurance?". International Journal of Sport Nutrition and Exercise Metabolism 21 (1): 71–84. February 2011. doi:10.1123/ijsnem.21.1.71. PMID 21411838. 
  61. "Nutritional supplements and ergogenic AIDS". Primary Care 40 (2): 487–505. June 2013. doi:10.1016/j.pop.2013.02.009. PMID 23668655. "Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training ...
    Physiologic and performance effects
     • Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation
     • Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40
     • Improved reaction time
     • Increased muscle strength and delayed muscle fatigue
     • Increased acceleration
     • Increased alertness and attention to task".
  62. "Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals". The American Journal of Clinical Nutrition 33 (5): 989–97. May 1980. doi:10.1093/ajcn/33.5.989. PMID 7369170. 
  63. "Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers". The American Journal of Clinical Nutrition 49 (1): 44–50. January 1989. doi:10.1093/ajcn/49.1.44. PMID 2912010. 
  64. "Comparison of changes in energy expenditure and body temperatures after caffeine consumption". Annals of Nutrition & Metabolism 39 (3): 135–42. 1995. doi:10.1159/000177854. PMID 7486839. 
  65. "Effect of Acute Caffeine Intake on the Fat Oxidation Rate during Exercise: A Systematic Review and Meta-Analysis". Nutrients 12 (12): 3603. November 2020. doi:10.3390/nu12123603. PMID 33255240. 
  66. "Effects of caffeine intake on muscle strength and power: a systematic review and meta-analysis". Journal of the International Society of Sports Nutrition 15: 11. 2018. doi:10.1186/s12970-018-0216-0. PMID 29527137. 
  67. "Effect of caffeine ingestion on muscular strength and endurance: a meta-analysis". Medicine and Science in Sports and Exercise 42 (7): 1375–87. July 2010. doi:10.1249/MSS.0b013e3181cabbd8. PMID 20019636. 
  68. "Caffeine ingestion enhances Wingate performance: a meta-analysis". European Journal of Sport Science 18 (2): 219–225. March 2018. doi:10.1080/17461391.2017.1394371. PMID 29087785. 
  69. "Effects of caffeine ingestion on rating of perceived exertion during and after exercise: a meta-analysis". Scandinavian Journal of Medicine & Science in Sports 15 (2): 69–78. April 2005. doi:10.1111/j.1600-0838.2005.00445.x. PMID 15773860. 
  70. "The Effect of Acute Caffeine Ingestion on Endurance Performance: A Systematic Review and Meta-Analysis". Sports Medicine 48 (8): 1913–1928. August 2018. doi:10.1007/s40279-018-0939-8. PMID 29876876. 
  71. "Establishing a relationship between the effect of caffeine and duration of endurance athletic time trial events: A systematic review and meta-analysis". Journal of Science and Medicine in Sport 22 (2): 232–238. February 2019. doi:10.1016/j.jsams.2018.07.022. PMID 30170953. 
  72. 72.0 72.1 72.2 72.3 "Caffeine in Food". Health Canada. 6 February 2012. 
  73. 73.0 73.1 "Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children". Food and Chemical Toxicology 109 (Pt 1): 585–648. November 2017. doi:10.1016/j.fct.2017.04.002. PMID 28438661. 
  74. 74.0 74.1 "Review: Trends, Safety, and Recommendations for Caffeine Use in Children and Adolescents". Journal of the American Academy of Child and Adolescent Psychiatry 58 (1): 36–45. January 2019. doi:10.1016/j.jaac.2018.06.030. PMID 30577937. 
  75. "Effects of caffeine on development and behavior in infancy and childhood: a review of the published literature". Food and Chemical Toxicology 40 (9): 1235–1242. September 2002. doi:10.1016/S0278-6915(02)00097-2. PMID 12204387. 
  76. "The Safety of Ingested Caffeine: A Comprehensive Review". Frontiers in Psychiatry 8 (80): 80. May 26, 2017. doi:10.3389/fpsyt.2017.00080. PMID 28603504. 
  77. The Addiction Casebook. American Psychiatric Pub. 2014. p. 49. ISBN 978-1-58562-458-4. 
  78. 78.0 78.1 "Sports drinks and energy drinks for children and adolescents: are they appropriate?". Pediatrics 127 (6): 1182–1189. June 2011. doi:10.1542/peds.2011-0965. PMID 21624882. 
  79. 79.0 79.1 79.2 79.3 "Coffee, Caffeine, and Health". The New England Journal of Medicine 383 (4): 369–378. July 2020. doi:10.1056/NEJMra1816604. PMID 32706535. 
  80. "Food Standards Agency publishes new caffeine advice for pregnant women". 
  81. "Caffeine in pregnancy". Archives of Gynecology and Obstetrics 280 (5): 695–8. November 2009. doi:10.1007/s00404-009-0991-6. PMID 19238414. 
  82. "Evaluation of the reproductive and developmental risks of caffeine". Birth Defects Research Part B: Developmental and Reproductive Toxicology 92 (2): 152–87. April 2011. doi:10.1002/bdrb.20288. PMID 21370398. 
  83. "Maternal caffeine intake during pregnancy is associated with risk of low birth weight: a systematic review and dose-response meta-analysis". BMC Medicine 12 (1): 174. September 2014. doi:10.1186/s12916-014-0174-6. PMID 25238871. 
  84. "Maternal caffeine intake during pregnancy and risk of pregnancy loss: a categorical and dose-response meta-analysis of prospective studies". Public Health Nutrition 19 (7): 1233–44. May 2016. doi:10.1017/S1368980015002463. PMID 26329421. 
  85. "Preconception care: caffeine, smoking, alcohol, drugs and other environmental chemical/radiation exposure". Reproductive Health 11 (Suppl 3): S6. September 2014. doi:10.1186/1742-4755-11-S3-S6. PMID 25415846. 
  86. "Coffee and gastrointestinal function: facts and fiction. A review". Scandinavian Journal of Gastroenterology. Supplement 34 (230): 35–9. 1999. doi:10.1080/003655299750025525. PMID 10499460. 
  87. "Gastric acid secretion and lower-esophageal-sphincter pressure in response to coffee and caffeine". The New England Journal of Medicine 293 (18): 897–9. October 1975. doi:10.1056/NEJM197510302931803. PMID 1177987. 
  88. Human Physiology: From Cells to Systems (1st Canadian ed.). Nelsen. 2009. pp. 613–9. ISBN 978-0-17-644107-4. 
  89. "Caffeine in the diet". MedlinePlus, US National Library of Medicine. 30 April 2013. 
  90. "Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes". The American Journal of Clinical Nutrition 74 (5): 694–700. November 2001. doi:10.1093/ajcn/74.5.694. PMID 11684540. 
  91. "Caffeine ingestion and fluid balance: a review". Journal of Human Nutrition and Dietetics 16 (6): 411–20. December 2003. doi:10.1046/j.1365-277X.2003.00477.x. PMID 19774754. 
  92. Modulation of adenosine receptor expression in the proximal tubule: a novel adaptive mechanism to regulate renal salt and water metabolism Am. J. Physiol. Renal Physiol. 1 July 2008 295:F35-F36
  93. "Really? The claim: caffeine causes dehydration". New York Times. 4 March 2008. 
  94. "Caffeine, fluid-electrolyte balance, temperature regulation, and exercise-heat tolerance". Exercise and Sport Sciences Reviews 35 (3): 135–40. July 2007. doi:10.1097/jes.0b013e3180a02cc1. PMID 17620932. 
  95. "A randomized trial to assess the potential of different beverages to affect hydration status: development of a beverage hydration index". The American Journal of Clinical Nutrition 103 (3): 717–23. March 2016. doi:10.3945/ajcn.115.114769. PMID 26702122. 
  96. "Caffeine and creatine use in sport". Annals of Nutrition & Metabolism 57 (Suppl 2): 1–8. 2010. doi:10.1159/000322696. PMID 21346331. 
  97. "Neuropsychiatric effects of caffeine". Advances in Psychiatric Treatment 11 (6): 432–439. 2005. doi:10.1192/apt.11.6.432. 
  98. "Caffeine challenge test and panic disorder: a systematic literature review". Expert Review of Neurotherapeutics 11 (8): 1185–95. August 2011. doi:10.1586/ern.11.83. PMID 21797659. 
  99. "Effects of caffeine on human behavior". Food and Chemical Toxicology 40 (9): 1243–55. September 2002. doi:10.1016/S0278-6915(02)00096-0. PMID 12204388. 
  100. "Caffeine abstention in the management of anxiety disorders". Psychological Medicine 19 (1): 211–4. February 1989. doi:10.1017/S003329170001117X. PMID 2727208. 
  101. "Caffeine, mental health, and psychiatric disorders". Journal of Alzheimer's Disease 20 (Suppl 1): S239–48. 2010. doi:10.3233/JAD-2010-1378. PMID 20164571. 
  102. "Coffee and caffeine consumption and depression: A meta-analysis of observational studies". The Australian and New Zealand Journal of Psychiatry 50 (3): 228–42. March 2016. doi:10.1177/0004867415603131. PMID 26339067. 
  103. "Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis of observational studies". Molecular Nutrition & Food Research 60 (1): 223–34. January 2016. doi:10.1002/mnfr.201500620. PMID 26518745. 
  104. "Chapter 34 Emotions". Psychiatry. 1. New York: John Wiley & Sons. 2015. pp. 557–558. ISBN 978-1-118-84547-9. "Table 34-12... Caffeine Intoxication – Euphoria" 
  105. "8. Substance Dependence". Psychiatry and Pedopsychiatry. Prague: Karolinum Press. 2017. pp. 153–154. ISBN 9788024633787. "At a high dose, caffeine shows a euphoric effect." 
  106. "Brain stimulation and addiction". Encyclopedia of Behavioral Neuroscience. Elsevier. 2010. pp. 214. ISBN 978-0-08-091455-8. "Therefore, caffeine and other adenosine antagonists, while weakly euphoria-like on their own, may potentiate the positive hedonic efficacy of acute drug intoxication and reduce the negative hedonic consequences of drug withdrawal." 
  107. Pharmacology for health professionals (3rd ed.). Chatswood, N.S.W.: Elsevier Australia. 2010. p. 433. ISBN 978-0-7295-3929-6. "In contrast to the amphetamines, caffeine does not cause euphoria, stereotyped behaviors or psychoses." 
  108. Neuropsychopharmacology and Therapeutics. John Wiley & Sons. 2015. p. 18. ISBN 978-1-118-38578-4. "However, in contrast to other psychoactive stimulants, such as amphetamine and cocaine, caffeine and the other methylxanthines do not produce euphoria, stereotyped behaviors or psychotic like symptoms in large doses." 
  109. 109.0 109.1 "Caffeine Use Disorder: A Review of the Evidence and Future Implications". Current Addiction Reports 1 (3): 186–192. September 2014. doi:10.1007/s40429-014-0024-9. PMID 25089257. 
  110. "16". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (3rd ed.). McGraw-Hill Education.. "True compulsive use of caffeine has not been documented, and, consequently, these drugs are not considered addictive." 
  111. "Caffeine addiction? Caffeine for youth? Time to act!". Addiction 109 (11): 1771–2. November 2014. doi:10.1111/add.12594. PMID 24984891. "Academics and clinicians, however, have not yet reached consensus about the potential clinical importance of caffeine addiction (or 'use disorder')". 
  112. "Caffeine Use Disorder: A Comprehensive Review and Research Agenda". Journal of Caffeine Research 3 (3): 114–130. September 2013. doi:10.1089/jcr.2013.0016. PMID 24761279. 
  113. Psychiatry (Fourth ed.). 2014. pp. 1446. ISBN 978-1-118-75336-1. 
  114. Testing for Abuse Liability of Drugs in Humans. Rockville, MD: U.S. Department of Health and Human Services Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse. p. 179. 
  115. "Cellular basis of memory for addiction". Dialogues in Clinical Neuroscience 15 (4): 431–43. December 2013. doi:10.31887/DCNS.2013.15.4/enestler. PMID 24459410. "DESPITE THE IMPORTANCE OF NUMEROUS PSYCHOSOCIAL FACTORS, AT ITS CORE, DRUG ADDICTION INVOLVES A BIOLOGICAL PROCESS: the ability of repeated exposure to a drug of abuse to induce changes in a vulnerable brain that drive the compulsive seeking and taking of drugs, and loss of control over drug use, that define a state of addiction. ... A large body of literature has demonstrated that such ΔFosB induction in D1-type NAc neurons increases an animal's sensitivity to drug as well as natural rewards and promotes drug self-administration, presumably through a process of positive reinforcement". 
  116. "Chapter III: Types of Addiction". Principles of addiction comprehensive addictive behaviors and disorders (1st ed.). Elsevier Academic Press. 2013. p. 784. ISBN 978-0-12-398361-9. Retrieved 11 July 2015. "Astrid Nehlig and colleagues present evidence that in animals caffeine does not trigger metabolic increases or dopamine release in brain areas involved in reinforcement and reward. A single photon emission computed tomography (SPECT) assessment of brain activation in humans showed that caffeine activates regions involved in the control of vigilance, anxiety, and cardiovascular regulation but did not affect areas involved in reinforcement and reward." 
  117. "SPECT assessment of brain activation induced by caffeine: no effect on areas involved in dependence". Dialogues in Clinical Neuroscience 12 (2): 255–63. 2010. doi:10.31887/DCNS.2010.12.2/anehlig. PMID 20623930. "Caffeine is not considered addictive, and in animals it does not trigger metabolic increases or dopamine release in brain areas involved in reinforcement and reward. ... these earlier data plus the present data reflect that caffeine at doses representing about two cups of coffee in one sitting does not activate the circuit of dependence and reward and especially not the main target area, the nucleus accumbens. ... Therefore, caffeine appears to be different from drugs of dependence like cocaine, amphetamine, morphine, and nicotine, and does not fulfil the common criteria or the scientific definitions to be considered an addictive substance.42". 
  118. "Caffeine use in children: what we know, what we have left to learn, and why we should worry". Neuroscience and Biobehavioral Reviews 33 (6): 793–806. June 2009. doi:10.1016/j.neubiorev.2009.01.001. PMID 19428492. "Through these interactions, caffeine is able to directly potentiate dopamine neurotransmission, thereby modulating the rewarding and addicting properties of nervous system stimuli.". 
  119. "ICD-10 Version:2015". World Health Organization. 2015. "
    F15 Mental and behavioural disorders due to use of other stimulants, including caffeine ...

    .2 Dependence syndrome
    A cluster of behavioural, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal state.
    The dependence syndrome may be present for a specific psychoactive substance (e.g., tobacco, alcohol, or diazepam), for a class of substances (e.g., opioid drugs), or for a wider range of pharmacologically different psychoactive substances. [Includes:]
    Chronic alcoholism
    Drug addiction"
  120. 120.0 120.1 120.2 120.3 Association American Psychiatry (2013). Diagnostic and statistical manual of mental disorders : DSM-5 (5th ed.). Washington [etc.]: American Psychiatric Publishing. pp. 792–795. ISBN 978-0-89042-555-8. 
  121. 121.0 121.1 "Caffeine use in children: what we know, what we have left to learn, and why we should worry". Neuroscience and Biobehavioral Reviews 33 (6): 793–806. June 2009. doi:10.1016/j.neubiorev.2009.01.001. PMID 19428492. 
  122. 122.0 122.1 122.2 Desk reference to the diagnostic criteria from DSM-5. Arlington, VA: American Psychiatric Association. 2013. pp. 238–239. ISBN 978-0-89042-556-5. 
  123. 123.0 123.1 "ICD-11 – Mortality and Morbidity Statistics". 
  124. American Psychiatric Association (2013). "Substance-Related and Addictive Disorders". American Psychiatric Publishing. pp. 1–2. Retrieved 18 November 2019.
  125. "Information about caffeine dependence". Johns Hopkins Medicine. 9 July 2003. 
  126. 126.0 126.1 126.2 "Actions of caffeine in the brain with special reference to factors that contribute to its widespread use". Pharmacological Reviews 51 (1): 83–133. March 1999. PMID 10049999. 
  127. "Caffeine intake and dementia: systematic review and meta-analysis". Journal of Alzheimer's Disease 20 (Suppl 1): S187-204. 2010. doi:10.3233/JAD-2010-091387. PMID 20182026. 
  128. "Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review". The Journal of Nutrition, Health & Aging 19 (3): 313–28. March 2015. doi:10.1007/s12603-014-0563-8. PMID 25732217. 
  129. "Coffee and liver diseases". Fitoterapia 81 (5): 297–305. July 2010. doi:10.1016/j.fitote.2009.10.003. PMID 19825397. 
  130. "Caffeine at high altitude: java at base cAMP". High Altitude Medicine & Biology 11 (1): 13–7. 2010. doi:10.1089/ham.2009.1077. PMID 20367483. 
  131. "Coffee and caffeine intake and incidence of type 2 diabetes mellitus: a meta-analysis of prospective studies". European Journal of Nutrition 53 (1): 25–38. February 2014. doi:10.1007/s00394-013-0603-x. PMID 24150256. "Dose-response analysis suggested that incidence of T2DM decreased ...14% [0.86 (0.82-0.91)] for every 200 mg/day increment in caffeine intake.". 
  132. "The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis". Nutrients 12 (6): 1860. June 2020. doi:10.3390/nu12061860. PMID 32580456. 
  133. "Caffeine intake, smoking, and risk of Parkinson disease in men and women". American Journal of Epidemiology 175 (11): 1200–7. June 2012. doi:10.1093/aje/kwr451. PMID 22505763. 
  134. "The effect of caffeine on intraocular pressure: a systematic review and meta-analysis". Graefe's Archive for Clinical and Experimental Ophthalmology 249 (3): 435–42. March 2011. doi:10.1007/s00417-010-1455-1. PMID 20706731. 
  135. Desk reference to the diagnostic criteria from DSM-5. Washington, DC: American Psychiatric Association. 2013. ISBN 978-0-89042-556-5. OCLC 825047464. 
  136. 136.0 136.1 "Caffeine (Systemic)". 25 May 2000. 
  137. "Neuropsychiatric effects of caffeine". Advances in Psychiatric Treatment 11 (6): 432–439. 2005. doi:10.1192/apt.11.6.432. 
  138. "Caffeinism: History, clinical features, diagnosis, and treatment". Caffeine and Activation Theory: Effects on Health and Behavior. CRC Press. 2007. pp. 331–344. ISBN 978-0-8493-7102-8. Retrieved 15 January 2014. 
  139. 139.0 139.1 "ICD-11 – Mortality and Morbidity Statistics". 
  140. American Psychiatric Association (22 May 2013) (in en). Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). American Psychiatric Association. doi:10.1176/appi.books.9780890425596. ISBN 978-0-89042-555-8. 
  141. "How to recognize caffeine overdose". Nursing 49 (4): 52–55. April 2019. doi:10.1097/01.NURSE.0000553278.11096.86. PMID 30893206. 
  142. 142.0 142.1 "Effects of low sodium perfusion on cardiac caffeine sensitivity and calcium uptake". Journal of Molecular and Cellular Cardiology 16 (11): 1037–1045. November 1984. doi:10.1016/s0022-2828(84)80016-4. PMID 6520875. 
  143. 143.0 143.1 "Caffeine Toxicity". StatPearls [Internet]. January 2019. PMID 30422505. 
  144. "Caffeine | C8H10N4O2". National Center for Biotechnology Information. 
  145. "Factors Affecting Caffeine Toxicity: A Review of the Literature". The Journal of Clinical Pharmacology and the Journal of New Drugs 7 (3): 131–141. 1967. doi:10.1002/j.1552-4604.1967.tb00034.x. 
  146. "Caffeine". StatPearls [Internet]. January 2019. PMID 30137774. 
  147. "Caffeine powder poses deadly risks". New York Times. 18 May 2015. 
  148. "Caffeine metabolism in patients with chronic liver disease". Scandinavian Journal of Clinical and Laboratory Investigation 55 (3): 229–42. May 1995. doi:10.3109/00365519509089618. PMID 7638557. 
  149. "Man died after overdosing on caffeine mints". The Independent. 11 October 2013. 
  150. "Warning over caffeine sweets after father dies from overdose". The Telegraph. 11 October 2013. 
  151. "Caffeine Drug Monographs".!/content/drug_monograph/6-s2.0-81. 
  152. "Interactions between alcohol and caffeine in relation to psychomotor speed and accuracy". Human Psychopharmacology 17 (3): 151–6. April 2002. doi:10.1002/hup.371. PMID 12404692. 
  153. 153.0 153.1 153.2 "Caffeine antagonism of alcohol-induced driving impairment". Drug and Alcohol Dependence 63 (2): 123–9. July 2001. doi:10.1016/s0376-8716(00)00196-4. PMID 11376916. 
  154. "Dissociative antagonistic effects of caffeine on alcohol-induced impairment of behavioral control". Experimental and Clinical Psychopharmacology 11 (3): 228–36. August 2003. doi:10.1037/1064-1297.11.3.228. PMID 12940502. 
  155. "Drug interactions with tobacco smoking. An update". Clinical Pharmacokinetics 36 (6): 425–438. June 1999. doi:10.2165/00003088-199936060-00004. PMID 10427467. 
  156. "Heavier smoking increases coffee consumption: findings from a Mendelian randomization analysis". International Journal of Epidemiology 46 (6): 1958–1967. December 2017. doi:10.1093/ije/dyx147. PMID 29025033. 
  157. "Clinical pharmacology of caffeine". Annual Review of Medicine 41: 277–88. 1990. doi:10.1146/ PMID 2184730. 
  158. "Treatment of acute migraine headache". American Family Physician 83 (3): 271–80. February 2011. PMID 21302868. 
  159. Practical management of pain (Fifth ed.). 12 September 2013. pp. 508–529. ISBN 978-0-323-08340-9. 
  160. "Vitamin B4". R&S Pharmchem. April 2011. 
  161. "Methylxanthines". StatPearls. September 29, 2021. PMID 32644591. Retrieved 15 November 2021. 
  162. 162.0 162.1 162.2 "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". Journal of Alzheimer's Disease 32 (4): 793–887. 2012. doi:10.3233/JAD-2012-121186. PMID 22886028. 
  163. 163.0 163.1 163.2 163.3 "An update on the mechanisms of the psychostimulant effects of caffeine". J. Neurochem. 105 (4): 1067–1079. 2008. doi:10.1111/j.1471-4159.2007.05196.x. PMID 18088379. "On the other hand, our 'ventral shell of the nucleus accumbens' very much overlaps with the striatal compartment...". 
  164. "World of Caffeine". World of Caffeine. 15 June 2013. 
  165. "Caffeine as a psychomotor stimulant: mechanism of action". Cellular and Molecular Life Sciences 61 (7–8): 857–72. April 2004. doi:10.1007/s00018-003-3269-3. PMID 15095008. 
  166. "Caffeine". International Union of Basic and Clinical Pharmacology. 
  167. "Caffeine inhibition of ionotropic glycine receptors". The Journal of Physiology 587 (Pt 16): 4063–75. August 2009. doi:10.1113/jphysiol.2009.174797. PMID 19564396. 
  168. 168.0 168.1 168.2 "Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine". Journal of Alzheimer's Disease 20 (Suppl 1): S35–49. 2010. doi:10.3233/JAD-2010-1400. PMID 20182056. "By targeting A1-A2A receptor heteromers in striatal glutamatergic terminals and A1 receptors in striatal dopaminergic terminals (presynaptic brake), caffeine induces glutamate-dependent and glutamate-independent release of dopamine. These presynaptic effects of caffeine are potentiated by the release of the postsynaptic brake imposed by antagonistic interactions in the striatal A2A-D2 and A1-D1 receptor heteromers.". 
  169. 169.0 169.1 "Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer". Neuropharmacology 104: 154–60. May 2016. doi:10.1016/j.neuropharm.2015.05.028. PMID 26051403. 
  170. 170.0 170.1 "Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer". Proceedings of the National Academy of Sciences of the United States of America 112 (27): E3609–18. July 2015. doi:10.1073/pnas.1507704112. PMID 26100888. Bibcode2015PNAS..112E3609B. "Adenosine A2A receptor (A2AR)-dopamine D2 receptor (D2R) heteromers are key modulators of striatal neuronal function. It has been suggested that the psychostimulant effects of caffeine depend on its ability to block an allosteric modulation within the A2AR-D2R heteromer, by which adenosine decreases the affinity and intrinsic efficacy of dopamine at the D2R.". 
  171. 171.0 171.1 "Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders". Psychopharmacology 233 (10): 1963–79. May 2016. doi:10.1007/s00213-016-4212-2. PMID 26786412. "The striatal A2A-D2 receptor heteromer constitutes an unequivocal main pharmacological target of caffeine and provides the main mechanisms by which caffeine potentiates the acute and long-term effects of prototypical psychostimulants.". 
  172. "Caffeine and adenosine". Journal of Alzheimer's Disease 20 (Suppl 1): S3-15. 2010. doi:10.3233/JAD-2010-1379. PMID 20164566. 
  173. "Cyclic nucleotide phosphodiesterases". The Journal of Allergy and Clinical Immunology 108 (5): 671–680. November 2001. doi:10.1067/mai.2001.119555. PMID 11692087. 
  174. "Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition". Clinics 63 (3): 321–328. June 2008. doi:10.1590/S1807-59322008000300006. PMID 18568240. 
  175. "Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages". American Journal of Respiratory and Critical Care Medicine 159 (2): 508–511. February 1999. doi:10.1164/ajrccm.159.2.9804085. PMID 9927365. 
  176. 176.0 176.1 "Leukotrienes: underappreciated mediators of innate immune responses". Journal of Immunology 174 (2): 589–594. January 2005. doi:10.4049/jimmunol.174.2.589. PMID 15634873. 
  177. "Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives". Toxicology Letters 55 (3): 335–342. March 1991. doi:10.1016/0378-4274(91)90015-X. PMID 2003276. 
  178. "Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase". International Journal of Molecular Sciences 14 (5): 9873–9882. May 2013. doi:10.3390/ijms14059873. PMID 23698772. 
  179. 179.0 179.1 "Pharmacokinetics and metabolism of natural methylxanthines in animal and man". Methylxanthines. 200. 19 August 2010. 33–91. doi:10.1007/978-3-642-13443-2_3. ISBN 978-3-642-13442-5. 
  180. "Absorption and subjective effects of caffeine from coffee, cola and capsules". Pharmacology, Biochemistry, and Behavior 58 (3): 721–6. November 1997. doi:10.1016/S0091-3057(97)00003-8. PMID 9329065. 
  181. "The absolute bioavailability of caffeine in man". European Journal of Clinical Pharmacology 24 (1): 93–8. 1983. doi:10.1007/bf00613933. PMID 6832208. 
  182. "Plasma and salivary pharmacokinetics of caffeine in man". European Journal of Clinical Pharmacology 21 (1): 45–52. 1981. doi:10.1007/BF00609587. PMID 7333346. 
  183. "Rectal use of ergotamine tartrate and caffeine alkaloid for the relief of migraine". The New England Journal of Medicine 250 (22): 936–8. June 1954. doi:10.1056/NEJM195406032502203. PMID 13165929. 
  184. "[The treatment of hyperemesis gravidarum with chlorobutanol-caffeine rectal suppositories in Denmark: practice and evidence]" (in da). Ugeskrift for Laeger 169 (22): 2122–3. May 2007. PMID 17553397. 
  185. "Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects". ISRN Pharmacology 2013 (147238): 147238. 8 January 2013. doi:10.1155/2013/147238. PMID 23533801. 
  186. "Drug Interaction: Caffeine Oral and Fluvoxamine Oral". Medscape Multi-Drug Interaction Checker. 
  187. "Caffeine". The Pharmacogenetics and Pharmacogenomics Knowledge Base. 
  188. "7-Methylxanthine". 
  189. "Myopia, its prevalence, current therapeutic strategy and recent developments: A Review". Indian J Ophthalmol 70 (8): 2788–2799. August 2022. doi:10.4103/ijo.IJO_2415_21. PMID 35918918. 
  190. "Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction". European Journal of Clinical Pharmacology 64 (12): 1147–61. December 2008. doi:10.1007/s00228-008-0553-z. PMID 18762933. 
  191. "Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption". PLOS Genetics 7 (4): e1002033. April 2011. doi:10.1371/journal.pgen.1002033. PMID 21490707. 
  192. 192.0 192.1 Susan Budavari, ed (1996). The Merck Index (12th ed.). Whitehouse Station, NJ: Merck & Co., Inc.. p. 1674. 
  193. This is the pKa for protonated caffeine, given as a range of values included in "Critical Compilation of pK(a) Values for Pharmaceutical Substances". Profiles of Drug Substances, Excipients, and Related Methodology (Academic Press) 33: 1–33 (15). 2007. doi:10.1016/S0099-5428(07)33001-3. ISBN 978-0-12-260833-9. PMID 22469138. 
  194. The Facts About Caffeine (Drugs). Benchmark Books (NY). 2006. p. 43. ISBN 978-0-7614-2242-6. 
  195. Organic Chemistry Pearls of Wisdom. Boston Medical Publishing Corp. 2001. p. 43. ISBN 978-1-58409-016-8. 
  196. "Chemistry of Caffeine". Chemistry Department, East Stroudsburg University. 
  197. "Caffeine biosynthesis". Trinity College Dublin. 
  198. "MetaCyc Pathway: caffeine biosynthesis I". SRI International. 
  199. 199.0 199.1 Beverages in Nutrition and Health. Totowa, NJ: Humana Press. 2003. p. 172. ISBN 978-1-58829-173-8. 
  200. 200.0 200.1 Swidinsky J, Baizer MM, "Process for the formylation of a 5-nitrouracil", US patent 2785162, published 12 March 1957, assigned to New York Quinine and Chemical Works, Inc.
  201. "The coffee genome provides insight into the convergent evolution of caffeine biosynthesis". Science 345 (6201): 1181–4. September 2014. doi:10.1126/science.1255274. PMID 25190796. Bibcode2014Sci...345.1181D. 
  202. "Convergent evolution of caffeine in plants by co-option of exapted ancestral enzymes". Proceedings of the National Academy of Sciences of the United States of America 113 (38): 10613–8. September 2016. doi:10.1073/pnas.1602575113. PMID 27638206. Bibcode2016PNAS..11310613H. 
  203. "How Plants Evolved Different Ways to Make Caffeine". The Scientist. 21 September 2016. 
  204. "A Novel Method of Caffeine Synthesis from Uracil". Synthetic Communications 33 (19): 3291–3297. 2003. doi:10.1081/SCC-120023986. 
  205. "Crystalline Caffeine". Bristol University. 
  206. 206.0 206.1 206.2 "How is coffee decaffeinated?". General Chemistry Online. 20 September 2005. 
  207. "Caffeine content of decaffeinated coffee". Journal of Analytical Toxicology (University of Florida News) 30 (8): 611–3. October 2006. doi:10.1093/jat/30.8.611. PMID 17132260. Retrieved 30 August 2013. 
  208. Disposition of Toxic Drugs and Chemicals in Man (11th ed.). Seal Beach, CA: Biomedical Publications. 2017. pp. 335–8. ISBN 978-0-692-77499-1. 
  209. "3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs". Life Sciences 43 (21): 1671–84. 1988. doi:10.1016/0024-3205(88)90478-x. PMID 3193854. 
  210. "N Substituted Xanthines: A Caffeine Analog Information File". 22 September 1995. 
  211. "Xanthines as adenosine receptor antagonists". Handbook of Experimental Pharmacology 200 (200): 151–99. 19 August 2010. doi:10.1007/978-3-642-13443-2_6. ISBN 978-3-642-13442-5. PMID 20859796. 
  212. Plant Polyphenols: Synthesis, Properties, Significance. Richard W. Hemingway, Peter E. Laks, Susan J. Branham (page 263)
  213. "28 Plants that Contain Caffeine". 
  214. "Caffeine and related methylxanthines: possible naturally occurring pesticides". Science 226 (4671): 184–7. October 1984. doi:10.1126/science.6207592. PMID 6207592. Bibcode1984Sci...226..184N. 
  215. "Purine alkaloid formation in buds and developing leaflets of Coffea arabica: Expression of an optimal defence strategy?". Phytochemistry 25 (3): 613–6. 1986. doi:10.1016/0031-9422(86)88009-8. 
  216. "Metabolism and excretion of caffeine during germination of Coffea arabica L". Plant and Cell Physiology 25 (8): 1431–6. 1984. doi:10.1093/oxfordjournals.pcp.a076854. 
  217. "Immunohistochemical localization of caffeine in young Camellia sinensis (L.) O. Kuntze (tea) leaves". Planta 237 (3): 849–58. March 2013. doi:10.1007/s00425-012-1804-x. PMID 23143222. 
  218. "Tea: the Plant and its Manufacture; Chemistry and Consumption of the Beverage". Caffeine Consumption. 1998. ISBN 978-0-429-12678-9. 
  219. "Caffeine Content of Food and Drugs". Center for Science in the Public Interest. 1996. 
  220. 220.0 220.1 "Caffeine Content of Beverages, Foods, & Medications". The Vaults of Erowid. 7 July 2006. 
  221. "Caffeine Content of Drinks". 
  222. 222.0 222.1 "Caffeine content of brewed teas". Journal of Analytical Toxicology 32 (8): 702–4. October 2008. doi:10.1093/jat/32.8.702. PMID 19007524. 
  223. 223.0 223.1 "Too Easy to be True. De-bunking the At-Home Decaffeination Myth". Elmwood Inn. 2009. 
  224. "Traditional Yerba Mate in Biodegradable Bag". Guayaki Yerba Mate. 
  225. 225.0 225.1 225.2 "An examination of consumer exposure to caffeine from commercial coffee and coffee-flavoured milk". Journal of Food Composition and Analysis 28 (2): 114. 2012. doi:10.1016/j.jfca.2012.09.001. 
  226. "Evaluation of xanthine derivatives in chocolate: nutritional and chemical aspects". European Food Research and Technology 205 (3): 175–84. 1997. doi:10.1007/s002170050148. INIST:2861730. 
  227. 227.0 227.1 "Caffeine". International Coffee Organization. 
  228. 228.0 228.1 "Coffee and Caffeine FAQ: Does dark roast coffee have less caffeine than light roast?". 
  229. 229.0 229.1 "All About Coffee: Caffeine Level". Jeremiah's Pick Coffee Co. 
  230. 230.0 230.1 "Tea preparation and its influence on methylxanthine concentration". Food Research International 29 (3–4): 325–330. 1996. doi:10.1016/0963-9969(96)00038-5. 
  231. "Nutrition and healthy eating". 
  232. "The xanthine content of guarana and its preparations". Int J Pharmacog 31 (3): 175–181. 1993. doi:10.3109/13880209309082937. ISSN 0925-1618. 
  233. "Drinking mate in Buenos Aires". 9 April 2012. 
  234. (in en) The Encyclopedia of Psychoactive Plants: Ethnopharmacology and Its Applications. Simon and Schuster. 2005. p. PT1235. ISBN 9781594776625. 
  235. "Flavoured milk and iced coffee sales on the rise". The Weekly Times (News Corp). 18 October 2017. 
  236. "Methylxanthines are the psycho-pharmacologically active constituents of chocolate". Psychopharmacology 176 (3–4): 412–9. November 2004. doi:10.1007/s00213-004-1898-3. PMID 15549276. 
  237. "Caffeine tablets or caplets". 
  238. The World of caffeine: The Science and Culture of the World's Most Popular Drug. Routledge. 2001. p. 195. ISBN 978-0-415-92723-9. Retrieved 15 January 2014. 
  239. "LeBron James Shills for Sheets Caffeine Strips, a Bad Idea for Teens, Experts Say". ABC News. 10 June 2011. 
  240. "Over The Limit:Americans young and old crave high-octane fuel, and doctors are jittery". U.S. News & World Report. 15 April 2007. 
  241. "F.D.A. Inquiry Leads Wrigley to Halt 'Energy Gum' Sales". New York Times. Associated Press. 8 May 2013. 
  242. "Some Common Questions". 
  243. "2012 – Breathable Foods, Inc. 3/5/12" (in en). 
  244. "Food Additives & Ingredients > Caffeinated Alcoholic Beverages". Food and Drug Administration. 17 November 2010. 
  245. Tea in China: The History of China's National Drink. Greenwood Press. 1992. p. 2. ISBN 978-0-313-28049-8. 
  246. The Classic of Tea: Origins & Rituals. Ecco Pr. 1995. ISBN 978-0-88001-416-8. 
  247. The World of Caffeine: The Science and Culture of the World's Most Popular Drug. Routledge. 2001. pp. 3–4. ISBN 978-0-415-92723-9. 
  248. ""Suave Molecules of Mocha" – Coffee, Chemistry, and Civilization". New Partisan. 7 March 2005. 
  249. "Dark Chocolate and (Pre-)Hypertension". Chocolate in Health and Nutrition. Humana Press. 21 June 2012. pp. 313–325. doi:10.1007/978-1-61779-803-0_23. ISBN 978-1-61779-802-3. 
  250. "The History of Cocoa Production in Trinidad and Tobago". 
  251. "A primer on PEF's Priority Commodities: an Industry Study on Cacao". Peace and Equity Foundation (Philippines). 2016. Retrieved May 21, 2022. 
  252. 252.0 252.1 "The function of black drink among the Creeks". Black Drink. University of Georgia Press. 2004. p. 123. ISBN 978-0-8203-2696-2. 
  253. "Ritual Black Drink consumption at Cahokia". Proceedings of the National Academy of Sciences of the United States of America 109 (35): 13944–9. August 2012. doi:10.1073/pnas.1208404109. PMID 22869743. Bibcode2012PNAS..10913944C. 
  254. Neueste phytochemische Entdeckungen zur Begründung einer wissenschaftlichen Phytochemie. Berlin: G. Reimer. 1820. pp. 144–159. Retrieved 8 January 2014. 
  255. This account appeared in Runge's book Hauswirtschaftlichen Briefen (Domestic Letters [i.e., personal correspondence]) of 1866. It was reprinted in: Johann Wolfgang von Goethe with F.W. von Biedermann, ed., Goethes Gespräche, vol. 10: Nachträge, 1755–1832 (Leipzig, (Germany): F.W. v. Biedermann, 1896), pages 89–96; see especially page 95
  256. The World of Caffeine: The Science and Culture of the World's Most Popular Drug. Routledge. 2001. pp. xvii–xxi. ISBN 978-0-415-92723-9. 
  257. (in de) Jahres-Bericht über die Fortschritte der physischen Wissenschaften von Jacob Berzelius. 4. 1825. "Caféin ist eine Materie im Kaffee, die zu gleicher Zeit, 1821, von Robiquet und Pelletier und Caventou entdekt wurde, von denen aber keine etwas darüber im Drucke bekannt machte." 
  258. (in de) Jahres-Bericht über die Fortschritte der physischen Wissenschaften von Jacob Berzelius. 7. 1828. "Es darf indessen hierbei nicht unerwähnt bleiben, dass Runge (in seinen phytochemischen Entdeckungen 1820, p. 146-7.) dieselbe Methode angegeben, und das Caffein unter dem Namen Caffeebase ein Jahr eher beschrieben hat, als Robiquet, dem die Entdeckung dieser Substanz gewöhnlich zugeschrieben wird, in einer Zusammenkunft der Societé de Pharmacie in Paris die erste mündliche Mittheilung darüber gab." 
  259. "Cafeine" (in fr). Dictionnaire de Médecine. 4. Paris: Béchet Jeune. 1822. pp. 35–36. Retrieved 3 March 2011. 
  260. "Café" (in fr). Dictionnaire Technologique, ou Nouveau Dictionnaire Universel des Arts et Métiers. 4. Paris: Thomine et Fortic. 1823. pp. 50–61. Retrieved 3 March 2011. 
  261. "Recherches sur la composition élémentaire et sur quelques propriétés caractéristiques des bases salifiables organiques" (in fr). Annales de Chimie et de Physique 24: 163–191. 1823. 
  262. "Note sur la Théine" (in fr). Nouvelle Bibliothèque Médicale 1: 477–479. 1827. 
  263. "Ueber Theïn und Caffeïn". Journal für Praktische Chemie 15: 280–284. 1838. doi:10.1002/prac.18380150124. 
  264. "Thein identisch mit Caffein". Liebig's Annalen der Chemie und Pharmacie 25: 63–66. 1838. doi:10.1002/jlac.18380250106. 
  265. Fischer began his studies of caffeine in 1881; however, understanding of the molecule's structure long eluded him. In 1895 he synthesized caffeine, but only in 1897 did he finally fully determine its molecular structure.
  266. "Nobel Prize Presentation Speech". 1902. 
  267. A new introduction to Islam. Chichester, West Sussex: Wiley-Blackwell. 2004. pp. 149–51. ISBN 978-1-4051-5807-7. 
  268. Encyclopedia of the Ottoman Empire. 2009. p. 138. 
  269. "Food Stories: The Sultan's Coffee Prohibition". 24 March 2006. 
  270. "By the King. A PROCLAMATION FOR THE Suppression of Coffee-Houses". 
  271. Pendergrast 2001, p. 13
  272. Pendergrast 2001, p. 11
  273. Bersten 1999, p. 53
  274. "Coca-Cola, caffeine, and mental deficiency: Harry Hollingworth and the Chattanooga trial of 1911". Journal of the History of the Behavioral Sciences 27 (1): 42–55. January 1991. doi:10.1002/1520-6696(199101)27:1<42::AID-JHBS2300270105>3.0.CO;2-1. PMID 2010614. 
  275. "The Rise and Fall of Cocaine Cola". 
  276. "CFR – Code of Federal Regulations Title 21". U.S. Food and Drug Administration. 21 August 2015. 
  277. "Sudden death of Ohio teen highlights dangers of caffeine powder". The Globe and Mail. The Associated Press (Columbus, Ohio: Phillip Crawley). 19 July 2014. 
  278. "Caffeinated energy drinks – a growing problem". Drug and Alcohol Dependence 99 (1–3): 1–10. January 2009. doi:10.1016/j.drugalcdep.2008.08.001. PMID 18809264. PMC 2735818. 
  279. 279.0 279.1 "Caffeine intake and its sources: A review of national representative studies". Critical Reviews in Food Science and Nutrition 58 (8): 1250–1259. May 2018. doi:10.1080/10408398.2016.1247252. PMID 28605236. 
  280. The War on Coffee. 1. 2018. p. 22. ISBN 978-0-9820787-6-1. 
  281. "Mormonism in the News: Getting It Right August 29". The Church of Jesus Christ of Latter-Day Saints. 2012. 
  282. "If Krishna does not accept my Chocolates, Who should I offer them to?" (in en-US). 
  283. The Politics of Narcotic Drugs: A Survey. 17 December 2010. pp. 189. ISBN 978-1857437591. 
  284. Encyclopedia of Islam. Infobase Publishing. 1 January 2009. p. 154. ISBN 978-1-4381-2696-8. Retrieved 1 November 2012. 
  285. A New Introduction to Islam. John Wiley & Sons. 24 August 2011. p. 149. ISBN 978-1-4443-5772-1. 
  286. "Newly Discovered Bacteria Lives on Caffeine". 24 May 2011. 
  287. "Why Caffeine is Toxic to Birds". Advin Systems. 
  288. "Caffeine". 
  289. "Using spider-web patterns to determine toxicity". NASA Tech Briefs 19 (4): 82. 29 April 1995. 
  290. "Chromosome doubling of haploids of common wheat with caffeine". Genome 40 (4): 552–8. August 1997. doi:10.1139/g97-072. PMID 18464846. 


  • Coffee, Sex & Health: A history of anti-coffee crusaders and sexual hysteria. Sydney: Helian Books. 1999. ISBN 978-0-9577581-0-0. 
  • Caffeinated: How Our Daily Habit Helps, Hurts, and Hooks Us. Plume. 2015. ISBN 978-0142181805. 
  • Uncommon Grounds: The History of Coffee and How It Transformed Our World. London: Texere. 2001. ISBN 978-1-58799-088-5. 
  • This Is Your Mind on Plants.. Penguin Press. 2021. ISBN 9780593296905. 

External links